DISEASE,ALTERATION,PMIDs,LT_LIT,MS_LIT,MS_CST,CST_CAT#,NOTES,PHOS_ID,ID_DP
Alzheimer's disease,mutation of site,16554819,36,5,3,6986; 3823,Pin1 binds to the pT668-Pro motif but not when mutated to Ala. ,APP_HUMAN(T668),DP0000001
breast cancer,increased,12244301,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,Expression of phosphorylated S473 in invasive breast carcinomas correlates with cytosolic p27.  ,AKT1_HUMAN(S473),DP0000002
Alzheimer's disease,increased,14970211,36,5,3,6986; 3823,,APP_HUMAN(T668),DP0000003
Alzheimer's disease,increased,14970211,3,2,1,,,APLP2_HUMAN(T736),DP0000004
prostate cancer,increased,12015328,4,1,0,,,AR_HUMAN(S16),DP0000005
prostate cancer,increased,12015328,10,3,0,,,AR_HUMAN(S651),DP0000006
prostate cancer,increased,12015328,3,1,0,,,AR_HUMAN(S426),DP0000007
prostate cancer,increased,12015328,10,5,0,,,AR_HUMAN(S310),DP0000008
prostate cancer,increased,12015328,3,2,1,,,AR_HUMAN(S258),DP0000009
prostate cancer,increased,12015328,8,10,0,,,AR_HUMAN(S96),DP0000010
prostate cancer,increased,12015328,15,1,0,,,AR_HUMAN(S83),DP0000011
breast cancer,increased,12118371,81,2,0,2511,,ESR1_HUMAN(S118),DP0000012
small-cell lung cancer,increased,16705183,165,5,0,2661; 2197; 12812,,CHEK2_HUMAN(T68),DP0000013
acute lymphocytic leukemia; chronic myelogenous leukemia; leukemia,increased,16855632,52,33,33,13748,,MYC_HUMAN(S62),DP0000014
colorectal cancer,mutation of site,11955436,60,3,0,4270; 13537; 9561; 9565,,CTNNB1_HUMAN(T41),DP0000015
colorectal cancer,mutation of site,11955436,72,3,12,4270; 2009; 13537; 9561,,CTNNB1_HUMAN(S37),DP0000016
colorectal cancer,mutation of site,11955436,29,6,0,19807; 70034; 9565; 9564,,CTNNB1_HUMAN(S45),DP0000017
colorectal cancer,mutation of site,11955436,68,3,2,4270; 2009; 13537; 9561,,CTNNB1_HUMAN(S33),DP0000018
Alzheimer's disease,increased,17064357,107,18,203,2338; 9154; 86128; 16211; 9121; 3958,,MAP2K1_HUMAN(S222),DP0000019
Alzheimer's disease,increased,17064357,50,31,142,9421,,RAF1_HUMAN(S259),DP0000020
Alzheimer's disease,increased,17064357,82,2,7,9427,,RAF1_HUMAN(S338),DP0000021
Alzheimer's disease,increased,17064357,111,12,83,9154; 86128; 9121; 3958,,MAP2K1_HUMAN(S218),DP0000022
Alzheimer's disease,increased,17064357,55,18,201,2338; 9154; 86128; 16211; 9121; 3958,,MAP2K2_HUMAN(S226),DP0000023
Alzheimer's disease,increased,17064357,33,1,1,,,RAF1_HUMAN(Y341),DP0000024
Alzheimer's disease,increased,17064357,59,12,83,9154; 86128; 9121; 3958,,MAP2K2_HUMAN(S222),DP0000025
Alzheimer's disease,increased,17064357,26,1,1,,,RAF1_HUMAN(Y340),DP0000026
colorectal carcinoma,increased,17148760,346,100,3046,70926; 6943; 2101,colon adenocarcinoma,SRC_HUMAN(Y419),DP0000027
Alzheimer's disease,increased,17634293,4,0,0,,,APP_HUMAN(T729),DP0000028
Bloom's syndrome,increased,17634426,167,22,4,13050; 4526; 5883,,ATM_HUMAN(S1981),DP0000029
rhabdomyosarcoma,increased,17848913,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000030
rhabdomyosarcoma,increased,17848913,585,11,18,43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038,,AKT1_HUMAN(T308),DP0000031
pancreatic cancer,increased,15467756,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000032
Burkitt's lymphoma,mutation of site,10866684,56,37,30,46650,,MYC_HUMAN(T58),DP0000033
papillary thyroid carcinoma; follicular thyroid carcinoma; anaplastic thyroid carcinoma,increased,15743786,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000034
papillary thyroid carcinoma; follicular thyroid carcinoma; anaplastic thyroid carcinoma,increased,15743786,24,0,1,,,CDKN1B_HUMAN(T157),DP0000035
papillary thyroid carcinoma; follicular thyroid carcinoma; anaplastic thyroid carcinoma,increased,15743786,25,0,6,,,CDKN1B_HUMAN(T198),DP0000036
breast cancer; colorectal cancer,increased,18922892,40,44,830,3251,involved in metastasis,CAV1_HUMAN(Y14),DP0000037
non-small cell lung adenocarcinoma,increased,18687633,43,57,967,4404,,EGFR_HUMAN(Y1172),DP0000038
non-small cell lung adenocarcinoma,increased,18687633,115,27,352,2236; 3777; 2234; 14565; 8543,,EGFR_HUMAN(Y1092),DP0000039
ventricular tachycardia; hypertrophic cardiomyopathy,increased,19060905,3,17,17,,,MAPK1_HUMAN(T190),DP0000040
cervical squamous cell carcinoma,increased,19079619,130,14,106,2971; 5536; 2976,,MTOR_HUMAN(S2448),DP0000041
cervical squamous cell carcinoma,increased,19079619,367,6,1,9209; 9206; 97596; 9234; 9205,,RPS6KB1_HUMAN(T412),DP0000042
Down syndrome,increased,19272359,42,20,0,,in the brain tissues isolated from children and young adults,CRYAB_HUMAN(S59),DP0000043
Down syndrome,increased,19272359,34,7,1,,in the brain tissues isolated from children and young adults,CRYAB_HUMAN(S45),DP0000044
Hodgkin's lymphoma,increased,19336568,2,0,0,,constitutive phosphorylation,TRAF2_HUMAN(S55),DP0000045
lung cancer,increased,19276349,7,8,1,,,RASSF1_HUMAN(S203),DP0000046
PSP,decreased,9920892,37,7,0,3370; 13041,TH isoform lacking S31 and S40 is overexpressed in PSP patients,TH_HUMAN(S31),DP0000047
PSP,decreased,9920892,54,10,11,2791,TH isoform lacking S31 and S40 is overexpressed in PSP patients,TH_HUMAN(S40),DP0000048
prostate cancer,increased,19147545,321,70,3065,9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075,,STAT3_HUMAN(Y705),DP0000049
Alzheimer's disease,increased,8318230,119,41,90,9632,,MAPT_HUMAN(S396),DP0000050
Alzheimer's disease,decreased,8930358,4,6,1,,,MAPT_HUMAN(S413),DP0000051
Alzheimer's disease,increased,12766916,86,38,14,,potential biomarker for Alzheimer's as distinct from other dementias. Phosphorylation occurs at early and later stages of AD.,MAPT_HUMAN(T231),DP0000052
Alzheimer's disease,increased,12766916,70,27,33,29957,potential biomarker for Alzheimer's as distinct from other dementias. Phosphorylation occurs at early and later stages of AD.,MAPT_HUMAN(S199),DP0000053
Alzheimer's disease; FTLD,increased,15136685,42,29,23,12885,"increased in early-onset Alzheimer disease patients, as compared to  frontotemporal lobar degeneration or normal control patients. AD was highest, and FTLD higher than normal controls.",MAPT_HUMAN(T181),DP0000054
X-linked hypophosphatemia,increased,19775205,1,3,0,,"ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH",SPP1_HUMAN(S117),DP0000055
HAM/TSP,increased,19678766,0,1,0,,,NEFL_HUMAN(S221),DP0000056
HAM/TSP,increased,19678766,0,1,1,,,NEFL_HUMAN(S215),DP0000057
HAM/TSP,increased,19678766,0,4,1,,,NEFL_HUMAN(S103),DP0000058
HAM/TSP,increased,19678766,2,18,0,,,NEFL_HUMAN(S472),DP0000059
X-linked hypophosphatemia,increased,19775205,1,4,0,,"ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH",SPP1_HUMAN(S126),DP0000060
X-linked hypophosphatemia,increased,19775205,1,3,0,,"ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH",SPP1_HUMAN(S120),DP0000061
X-linked hypophosphatemia,increased,19775205,1,4,0,,"ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH",SPP1_HUMAN(S123),DP0000062
X-linked hypophosphatemia,increased,19775205,1,4,0,,"ASARM peptide carrying phosphorylated residues S117, S120, S123, S126 and S129 contributes towards the hypomineralization occuring in XLH",SPP1_HUMAN(S129),DP0000063
hepatitis,decreased,18316359,79,7,48,84192; 9461,nonalcoholic steatohepatitis (NASH),FOXO1_HUMAN(S256),DP0000064
hepatitis,decreased,18316359,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,nonalcoholic steatohepatitis (NASH),AKT1_HUMAN(S473),DP0000065
Kaposi's sarcoma,increased,20333249,21,27,30,3541,,NPM1_HUMAN(T199),DP0000066
atrial fibrillation,increased,20056922,48,6,5,,,RYR2_HUMAN(S2814),DP0000067
kidney cancer,increased; translocation,19920202,39,19,5,3521,nuclear localization,MDM2_HUMAN(S166),DP0000068
sporadic inclusion-body myositis,increased,19878439,75,125,4206,,,GSK3B_HUMAN(Y216),DP0000069
breast cancer,increased,19940156,39,5,0,42101; 64508,high S167 phosphorylation in tamoxifen resistant tumors,ESR1_HUMAN(S167),DP0000070
lymphoma,increased,20224723,413,40,227,9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558,"mantle cell lymphoma, 67% of tumors showed positive S9 phosphorylation.",GSK3B_HUMAN(S9),DP0000071
breast cancer,increased,20179234,16,0,0,,,ESR1_HUMAN(S305),DP0000072
Parkinson's disease,decreased,19800394,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000073
glioblastoma multiforme,decreased,19941816,2,95,78,,,CTNNA1_HUMAN(S641),DP0000074
breast cancer,increased,20333297,2,1,0,,,AKT1_HUMAN(Y176),DP0000075
breast cancer,increased,20333297,6,27,235,3138,,TNK2_HUMAN(Y284),DP0000076
HIV Encephalitis,increased,20448061,4,2,84,,,GRIN2A_HUMAN(Y1325),DP0000077
breast cancer,increased,20418363,23,1,0,,"S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered ""good"" factors. T311 and S559 have a HR > 1 are considered ""bad"" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. ",ESR1_HUMAN(S106),DP0000078
breast cancer,increased,20418363,7,0,0,,"S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered ""good"" factors. T311 and S559 have a HR > 1 are considered ""bad"" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. ",ESR1_HUMAN(T311),DP0000079
breast cancer,increased,20418363,39,5,0,42101; 64508,"S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered ""good"" factors. T311 and S559 have a HR > 1 are considered ""bad"" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. ",ESR1_HUMAN(S167),DP0000080
breast cancer,increased,20418363,4,0,0,,"S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered ""good"" factors. T311 and S559 have a HR > 1 are considered ""bad"" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. ",ESR1_HUMAN(S282),DP0000081
breast cancer,increased,20418363,4,1,0,,"S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered ""good"" factors. T311 and S559 have a HR > 1 are considered ""bad"" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. ",ESR1_HUMAN(S559),DP0000082
breast cancer,increased,20418363,10,3,0,,"S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered ""good"" factors. T311 and S559 have a HR > 1 are considered ""bad"" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. ",ESR1_HUMAN(S294),DP0000083
breast cancer,increased,20418363,22,1,0,,"S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered ""good"" factors. T311 and S559 have a HR > 1 are considered ""bad"" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. ",ESR1_HUMAN(S104),DP0000084
breast cancer,increased,20418363,81,2,0,2511,"S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered ""good"" factors. T311 and S559 have a HR > 1 are considered ""bad"" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. ",ESR1_HUMAN(S118),DP0000085
tuberous sclerosis,increased,12150915,52,13,48,3617; 3611,,TSC2_HUMAN(T1462),DP0000086
tuberous sclerosis,increased,12150915,20,31,50,3615,,TSC2_HUMAN(S939),DP0000087
Wilm's tumor,deletion of site,12239584,29,6,0,19807; 70034; 9565; 9564,Observed frequent mutations of S45 of beta-catenin in Wilm's tumors.,CTNNB1_HUMAN(S45),DP0000088
ataxia-telangiectasic cancer,decreased,12447382,19,14,67,,,SMC1A_HUMAN(S966),DP0000089
Fanconi's anaemia,,15299017,2,1,0,,,FANCG_HUMAN(S7),DP0000090
Waardenburg syndrome type 2,mutation of site,10587587,3,1,0,,,MITF_HUMAN(S298),DP0000091
breast cancer,increased,11507039,20,8,55,88106; 9271; 3787; 4060; 5315; 9563; 4070; 15116; 4051; 5102; 4075; 5012; 4071; 8599; 4058; 11962; 2336; 2337; 12694,,AKT2_HUMAN(S474),DP0000092
leukemia,translocation,15256422,4,13,323,,,ABL1_HUMAN(Y257),DP0000093
medullary thyroid carcinoma,mutation of site,15753368,2,0,0,,,RET_HUMAN(Y791),DP0000094
medullary thyroid carcinoma,mutation of site,15753368,1,0,0,,,RET_HUMAN(S891),DP0000095
spinocerebellar ataxia type 1,increased,15757972,16,25,3,,,ATXN1_HUMAN(S775),DP0000096
Xeroderma pigmentosum,mutation of site,11955452,10,2,0,,,RARA_HUMAN(S77),DP0000097
chronic myelogenous leukemia,,16158058,1,2,37,,phosphorylation of this site has a positive role in survival of Bcr/Abl-positive CML cells,RB1_HUMAN(Y805),DP0000098
synucleinopathy; Parkinson's disease,increased,12505616,42,5,0,23706,,SNCA_HUMAN(S129),DP0000099
Alzheimer's disease,increased,16364302,101,36,109,9204,p70S6K T421/S424 phosphorylation correlates with tau phosphorylation in AD brains,RPS6KB1_HUMAN(T444),DP0000100
Alzheimer's disease,increased,16364302,96,51,247,9204,p70S6K T421/S424 phosphorylation correlates with tau phosphorylation in AD brains,RPS6KB1_HUMAN(S447),DP0000101
esophageal cancer,mutation of site,16357520,6,0,0,,,EGFR_HUMAN(S768),DP0000102
cervical cancer,increased,15958277,36,7,1,,,GJA1_HUMAN(S282),DP0000103
cervical cancer,increased,15958277,37,6,1,,,GJA1_HUMAN(S279),DP0000104
cystic fibrosis,decreased,16424149,16,12,14,,increased phosphorylation caused by curcumin rescue of CFTR F508 deletion,KRT18_HUMAN(S53),DP0000105
rheumatoid arthritis,increased,16778989,13,7,0,,TAT-Ser345 peptide (ARPGPQSPGSPL) may have potenital antiinflammatory properties,NCF1_HUMAN(S345),DP0000106
synucleinopathy,increased,16847063,42,5,0,23706,,SNCA_HUMAN(S129),DP0000107
acute lymphocytic leukemia,deletion of site,16880534,1,0,0,,mutation of four serines (2521-2524) to alanine increases leukemogenetic activity of Notch 1; region deleted in ALL,NOTCH1_HUMAN(S2524),DP0000108
acute lymphocytic leukemia,deletion of site,16880534,1,0,0,,mutation of four serines (2521-2524) to alanine increases leukemogenetic activity of Notch 1; region deleted in ALL,NOTCH1_HUMAN(S2523),DP0000109
acute lymphocytic leukemia,deletion of site,16880534,1,0,0,,mutation of four serines (2521-2524) to alanine increases leukemogenetic activity of Notch 1; region deleted in ALL,NOTCH1_HUMAN(S2522),DP0000110
acute lymphocytic leukemia,deletion of site,16880534,1,0,0,,mutation of four serines (2521-2524) to alanine increases leukemogenetic activity of Notch 1; region deleted in ALL,NOTCH1_HUMAN(S2521),DP0000111
ataxia-telangiectasic cancer,decreased,16931761,3,0,1,,alternation: mutation of ATM protein kinase ,COP1_HUMAN(S387),DP0000112
Alzheimer's disease; schizophrenia,increased,16925597,48,118,91,,increased in some schizophrenic patients; decreased in patients with Alzheimer's disease,STMN1_HUMAN(S25),DP0000113
Alzheimer's disease; schizophrenia,increased,16925597,45,110,166,4191; 3426,increased in some schizophrenic patients; not significantly changed in patients with the Alzheimer's disease,STMN1_HUMAN(S38),DP0000114
Parkinson's disease,decreased,17327227,3,1,0,,,PRKN_HUMAN(S131),DP0000115
atherosclerosis,decreased,15249501,57,100,289,9709; 2406; 2401; 11892,,HSPB1_HUMAN(S82),DP0000116
ataxia-telangiectasia,decreased,9733515,402,8,0,9235; 8695; 9284; 9286; 8514; 12571; 4030,,TP53_HUMAN(S15),DP0000117
breast cancer,increased,17418864,11,27,145,2347,,CHEK1_HUMAN(S280),DP0000118
tuberous sclerosis,increased,17671177,7,9,1,40729,,TSC2_HUMAN(S664),DP0000119
glioblastoma multiforme,increased,17575160,43,6,12,2235,,EGFR_HUMAN(Y1016),DP0000120
prostate cancer,increased,17045208,346,100,3046,70926; 6943; 2101,phosphorylated Src and AR higher in hormone-refractory prostate cancers than hormone-sensitive ones.,SRC_HUMAN(Y419),DP0000121
prostate cancer,increased,17045208,3,1,0,,phosphorylated Src and AR higher in hormone-refractory prostate cancers than hormone-sensitive ones.,AR_HUMAN(Y535),DP0000122
bladder cancer,increased,17062641,46,35,740,3129; 3077; 3126; 4091; 4033; 12468,,MET_HUMAN(Y1234),DP0000123
bladder cancer,increased,17062641,13,26,366,3135,,MET_HUMAN(Y1003),DP0000124
bladder cancer,increased,17062641,44,16,442,3129; 3077; 3126; 4091; 4033; 12468,,MET_HUMAN(Y1235),DP0000125
leukemia,increased,17164333,4,13,323,,"elevated in drug resistant leukemias with T315I mutations in Abl, and is associated with increased oncogenicity",ABL1_HUMAN(Y257),DP0000126
colorectal cancer,increased,17371847,3,1,3,,In cancers where Erk1/2 is upregulated,FOSL1_HUMAN(S252),DP0000127
colorectal cancer,increased,17371847,3,8,6,3880; 5841,In cancers where Erk1/2 is upregulated,FOSL1_HUMAN(S265),DP0000128
melanoma skin cancer,increased,15502804,63,43,112,8974; 8957; 8516; 4277; 9308; 11917,phosphorylation increases as goes from melanocytic nevus to metastatic tumor; increased p-Rb correlates with a worse prognosis,RB1_HUMAN(S807),DP0000129
melanoma skin cancer,increased,15502804,62,38,80,8974; 8957; 8516; 4277; 9308; 11917,phosphorylation increases as goes from melanocytic nevus to metastatic tumor; increased p-Rb correlates with a worse prognosis,RB1_HUMAN(S811),DP0000130
melanoma skin cancer,increased,15502804,44,16,94,9301,phosphorylation increases as goes from melanocytic nevus to metastatic tumor; increased p-Rb correlates with a worse prognosis,RB1_HUMAN(S795),DP0000131
vesicoureteral reflux,mutation of site,18273880,1,0,0,,mutation of G691 to serine due to SNP,RET_HUMAN(G691),DP0000132
Parkinson's disease,increased,11813001,42,5,0,23706,,SNCA_HUMAN(S129),DP0000133
Parkinson's disease,increased,14579119,42,5,0,23706,,SNCA_HUMAN(S129),DP0000134
Alzheimer's disease,increased,16645045,46,19,42,77348,,MAPT_HUMAN(S214),DP0000135
breast cancer,increased,19104930,4,0,0,,,ESR1_HUMAN(S282),DP0000136
Alzheimer's disease,increased,11943712,105,48,69,91600; 35834; 20194; 98523,S396 and S304 are hyperphosphorylated in the CSF of AD patients as compared with normal controls. -useful diagnostic marker of AD,MAPT_HUMAN(S404),DP0000137
diabetes mellitus,decreased,17272402,585,11,18,43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038,,AKT1_HUMAN(T308),DP0000138
diabetes mellitus,decreased,17272402,1,1,1,,,INSR_HUMAN(Y1149),DP0000139
"cancer, squamous cell carcinoma",decreased,16115915,19,0,0,,,WWOX_HUMAN(Y33),DP0000140
nephrogenic diabetes insipidus,decreased,16120822,70,7,0,,,AQP2_HUMAN(S256),DP0000141
FTLD; ALS,increased,18546284,10,1,0,,,TARDBP_HUMAN(S404),DP0000142
FTLD; ALS,increased,18546284,4,1,0,,,TARDBP_HUMAN(S379),DP0000143
FTLD; ALS,increased,18546284,10,2,0,,,TARDBP_HUMAN(S403),DP0000144
FTLD; ALS,increased,18546284,40,1,0,,,TARDBP_HUMAN(S409),DP0000145
FTLD; ALS,increased,18546284,40,1,0,,,TARDBP_HUMAN(S410),DP0000146
breast cancer,increased,10713673,74,2,22,3291,breast carcinoma cell invasion,PTK2B_HUMAN(Y402),DP0000147
angiosarcoma,mutation of site,10728596,1,0,0,,,GJA4_HUMAN(P319),DP0000148
myxoid liposarcoma,translocation,18620545,6,2,0,,t(12;16)(q13;p11) translocation,FUS_HUMAN(S42),DP0000149
fibrosarcoma of soft tissue,mutation of site,18621744,7,3,39,,experimental mustation of site interferes with tumor cell proliferation and tumor growth,MMP14_HUMAN(Y573),DP0000150
breast cancer,increased,18353781,321,70,3065,9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075,,STAT3_HUMAN(Y705),DP0000151
mantle cell lymphoma,increased,18467333,39,19,5,3521,,MDM2_HUMAN(S166),DP0000152
mantle cell lymphoma,increased,18467333,12,8,2,,,MDM2_HUMAN(S186),DP0000153
testicular cancer,increased,15846060,197,29,29,2577; 9719; 5438; 9720; 20304; 4309; 5763; 85410; 9718; 80312,,H2AFX_HUMAN(S139),DP0000154
testicular cancer,increased,15846060,167,22,4,13050; 4526; 5883,,ATM_HUMAN(S1981),DP0000155
DCM,decreased,18790732,21,29,2,,in patients carrying P20L substitution in Hsp20 ,HSPB6_HUMAN(S16),DP0000156
chronic lymphocytic leukemia,increased,12393602,42,20,108,9379; 9374; 93292; 2060; 38938,,PRKCD_HUMAN(T507),DP0000157
breast cancer,increased,19104930,7,0,0,,,ESR1_HUMAN(T311),DP0000158
Alzheimer's disease,increased,11943712,119,41,90,9632,S396 and S304 are hyperphosphorylated in the CSF of AD patients as compared with normal controls. -useful diagnostic marker of AD,MAPT_HUMAN(S396),DP0000159
breast cancer,increased,19104930,81,2,0,2511,,ESR1_HUMAN(S118),DP0000160
breast cancer,increased,19104930,39,5,0,42101; 64508,,ESR1_HUMAN(S167),DP0000161
breast cancer,increased,19104930,23,1,0,,,ESR1_HUMAN(S106),DP0000162
breast cancer,increased,19104930,4,1,0,,,ESR1_HUMAN(S559),DP0000163
breast cancer,increased,19104930,22,1,0,,,ESR1_HUMAN(S104),DP0000164
breast cancer,increased,19104930,10,3,0,,,ESR1_HUMAN(S294),DP0000165
FTLD; ALS,increased,18656473,40,1,0,,,TARDBP_HUMAN(S410),DP0000166
FTLD; ALS,increased,18656473,40,1,0,,,TARDBP_HUMAN(S409),DP0000167
breast cancer,increased,19036157,9,32,2,2900,,YBX1_HUMAN(S102),DP0000168
FTLD; ALS,increased,19235466,40,1,0,,phosphorylated and degraded TDP-43 has been found in brains of FTLD and ALS patients,TARDBP_HUMAN(S409),DP0000169
FTLD; ALS,increased,19235466,40,1,0,,phosphorylated and degraded TDP-43 has been found in brains of FTLD and ALS patients,TARDBP_HUMAN(S410),DP0000170
Parkinson's disease; ALS,increased,8858002,105,48,69,91600; 35834; 20194; 98523,Guam ALS/parkinsonism-dementia complex,MAPT_HUMAN(S404),DP0000171
lymphoma,increased,17483340,16,60,1189,5431; 3703; 13328,Anaplastic large cell lymphomas (ALCL) which contain NPM-ALK translocations,PTPN11_HUMAN(Y584),DP0000172
lymphoma,increased,17483340,27,24,442,3751,Anaplastic large cell lymphomas (ALCL) which contain NPM-ALK translocations,PTPN11_HUMAN(Y546),DP0000173
myopathy,mutation of site,18061454,2,0,0,,,DES_HUMAN(S13),DP0000174
breast cancer,increased,17495324,413,40,227,9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558,"phosphorylation correlates with Mcl-1 and poor prognosis in breast cancer, in multiple cell lines and primary human cancer samples. ",GSK3B_HUMAN(S9),DP0000175
ARVC,mutation of site,12373648,1,0,0,,,DSP_HUMAN(S299),DP0000176
hepatocellular carcinoma,increased,11826406,10,1,0,,,RXRA_HUMAN(S260),DP0000177
Alzheimer's disease,increased,15324364,86,38,14,,AD diagnostic tool,MAPT_HUMAN(T231),DP0000178
myotonic dystrophy type1,increased,18570922,3,8,1,,"indirect evidence - Akt site, and Akt activity increased in DM1",CELF1_HUMAN(S28),DP0000179
ataxia-telangiectasia,decreased,10866324,8,0,0,,,BRCA1_HUMAN(S1387),DP0000180
ataxia-telangiectasia,decreased,10866324,13,1,1,,,BRCA1_HUMAN(S1423),DP0000181
ataxia-telangiectasia,decreased,10866324,6,4,1,,,BRCA1_HUMAN(S1457),DP0000182
ovarian cancer,increased,15208673,130,14,106,2971; 5536; 2976,,MTOR_HUMAN(S2448),DP0000183
liver cancer,increased,15684384,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000184
schizophrenia,mutation of site,15900227,2,7,9,,,SYN3_HUMAN(S470),DP0000185
GIST,increased,15007386,17,5,52,3391,,KIT_HUMAN(Y721),DP0000186
GIST,increased,15007386,5,4,22,3073,,KIT_HUMAN(Y703),DP0000187
PSP,increased,18315566,39,33,25,,,MAPT_HUMAN(S235),DP0000188
PSP,increased,18315566,13,39,70,91600; 35834; 20194; 98523,,MAPT_HUMAN(S400),DP0000189
PSP,increased,18315566,106,50,116,39357,,MAPT_HUMAN(S202),DP0000190
PSP,increased,18315566,105,48,69,91600; 35834; 20194; 98523,,MAPT_HUMAN(S404),DP0000191
PSP,increased,18315566,86,38,14,,,MAPT_HUMAN(T231),DP0000192
PSP,increased,18315566,119,41,90,9632,,MAPT_HUMAN(S396),DP0000193
PSP,increased,18315566,5,27,26,91600; 35834; 20194; 98523,,MAPT_HUMAN(T403),DP0000194
PSP,increased,18315566,20,26,6,,,MAPT_HUMAN(T217),DP0000195
PSP,increased,18315566,42,29,23,12885,,MAPT_HUMAN(T181),DP0000196
PSP,increased,18315566,2,8,0,20296,,MAPT_HUMAN(S46),DP0000197
breast adenocarcinoma,increased,16461563,213,13,1,3458; 5764; 53348; 29237; 9701; 3465; 8481; 8552; 9711; 3642; 9706; 3377; 9606; 3475,,HIST1H3A_HUMAN(S10),DP0000198
kidney cancer,increased,16914575,27,6,125,3133; 3121,,MET_HUMAN(Y1349),DP0000199
chronic lymphocytic leukemia,increased,16940331,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000200
chronic lymphocytic leukemia,increased,16940331,585,11,18,43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038,,AKT1_HUMAN(T308),DP0000201
bipolar disprder,increased,16806104,413,40,227,9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558,,GSK3B_HUMAN(S9),DP0000202
breast cancer,increased,17130135,12,1,0,2111; 43507,,MKNK1_HUMAN(T255),DP0000203
breast cancer,increased,17157789,39,5,0,42101; 64508,,ESR1_HUMAN(S167),DP0000204
melanoma skin cancer,decreased,17785551,138,6,64,25809; 8009; 8062; 9174; 9167; 5375; 8183; 7649,,STAT1_HUMAN(Y701),DP0000205
chronic myelogenous leukemia,increased,17431132,41,19,69,3001,,NBN_HUMAN(S343),DP0000206
AIDS-related lymphoma,decreased,17310999,56,37,30,46650,primary effusion lymphoma,MYC_HUMAN(T58),DP0000207
breast cancer,increased,17130135,13,1,1,2111; 43507,,MKNK1_HUMAN(T250),DP0000208
colorectal carcinoma,decreased,17974954,126,24,968,2105,,SRC_HUMAN(Y530),DP0000209
prostate cancer,increased,18066052,15,5,0,9767; 9764,,HIST1H3A_HUMAN(T11),DP0000210
gastric carcinoma,mutation of site,16786156,1,0,0,,,TLR4_HUMAN(T175),DP0000211
Alzheimer's disease,increased,17314187,42,29,23,12885,,MAPT_HUMAN(T181),DP0000212
retinitis pigmentosa,mutation of site,17335001,2,0,1,,,NRL_HUMAN(S50),DP0000213
breast cancer,mutation of site,15800615,7,1,0,,,BRCA2_HUMAN(S3291),DP0000214
melanoma skin cancer,increased,12499277,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000215
ovarian cancer,increased,15208673,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000216
ovarian cancer,increased,15208673,413,40,227,9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558,,GSK3B_HUMAN(S9),DP0000217
bladder cancer,increased,15361851,165,5,0,2661; 2197; 12812,,CHEK2_HUMAN(T68),DP0000218
AIDS-related lymphoma; B cell lymphoma; Burkitt's lymphoma,mutation of site,10706881,56,37,30,46650,,MYC_HUMAN(T58),DP0000219
breast cancer,increased,16168121,81,2,0,2511,,ESR1_HUMAN(S118),DP0000220
breast cancer,increased,16168121,39,5,0,42101; 64508,,ESR1_HUMAN(S167),DP0000221
schizophrenia,decreased,14745448,413,40,227,9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558,,GSK3B_HUMAN(S9),DP0000222
T cell leukemia,mutation of site,11042698,68,3,0,9289,,TP53_HUMAN(S37),DP0000223
FTLD; ALS,increased,19125255,40,1,0,,,TARDBP_HUMAN(S410),DP0000224
FTLD; ALS,increased,19125255,40,1,0,,,TARDBP_HUMAN(S409),DP0000225
hepatocellular carcinoma,,19115199,6,0,0,3104,,SMAD2_HUMAN(S255),DP0000226
hepatocellular carcinoma,,19115199,10,2,1,,,ITGB1_HUMAN(T789),DP0000227
hepatocellular carcinoma,,19115199,8,0,0,3104,,SMAD2_HUMAN(S245),DP0000228
hepatocellular carcinoma,,19115199,6,0,0,3104,,SMAD2_HUMAN(S250),DP0000229
hepatocellular carcinoma,,19115199,11,1,1,,,ITGB1_HUMAN(T788),DP0000230
prostate cancer,increased,18829527,145,53,67,9134; 87544; 58978; 9136; 49081; 71958; 34911; 94994,,STAT3_HUMAN(S727),DP0000231
type 2 diabetes,increased,12765939,1154,100,2017,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK3_HUMAN(T202),DP0000232
type 2 diabetes,increased,12765939,38,23,1,2388,,IRS1_HUMAN(S636),DP0000233
type 2 diabetes,increased,12765939,1177,129,3549,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK3_HUMAN(Y204),DP0000234
type 2 diabetes,increased,12765939,1104,117,2416,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK1_HUMAN(T185),DP0000235
type 2 diabetes,increased,12765939,1126,149,4003,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK1_HUMAN(Y187),DP0000236
Lafora disease,,19171932,1,7,1,,,PPP1R3C_HUMAN(S33),DP0000237
IPF,increased,19104148,21,2,20,,accumulation of pY654??-catenin in myofibroblasts,CTNNB1_HUMAN(Y654),DP0000238
Fetal growth restriction,increased; molecular association,19193607,11,9,0,,,IGFBP1_HUMAN(S144),DP0000239
Alzheimer's disease,increased,8506352,106,50,116,39357,,MAPT_HUMAN(S202),DP0000240
Parkinson's disease; ALS,increased,8858002,42,29,23,12885,Guam ALS/parkinsonism-dementia complex,MAPT_HUMAN(T181),DP0000241
Alzheimer's disease,increased,19451179,37,13,5,,,MAPT_HUMAN(T212),DP0000242
Alzheimer's disease,increased,19451179,119,41,90,9632,,MAPT_HUMAN(S396),DP0000243
Alzheimer's disease,increased,19451179,70,27,33,29957,,MAPT_HUMAN(S199),DP0000244
Alzheimer's disease,increased,19451179,20,26,6,,,MAPT_HUMAN(T217),DP0000245
Alzheimer's disease,increased,19451179,105,48,69,91600; 35834; 20194; 98523,,MAPT_HUMAN(S404),DP0000246
Alzheimer's disease,increased,19451179,84,20,2,,,MAPT_HUMAN(S262),DP0000247
Alzheimer's disease,increased,19451179,74,21,26,43964; 49561; 53001,,MAPT_HUMAN(T205),DP0000248
Alzheimer's disease,increased,19451179,106,50,116,39357,,MAPT_HUMAN(S202),DP0000249
Alzheimer's disease,increased,19451179,32,7,0,,,MAPT_HUMAN(S422),DP0000250
Parkinson's disease; ALS,increased,8858002,119,41,90,9632,Guam ALS/parkinsonism-dementia complex,MAPT_HUMAN(S396),DP0000251
Parkinson's disease; ALS,increased,8858002,32,7,0,,Guam ALS/parkinsonism-dementia complex,MAPT_HUMAN(S422),DP0000252
Parkinson's disease; ALS,increased,8858002,84,20,2,,Guam ALS/parkinsonism-dementia complex,MAPT_HUMAN(S262),DP0000253
Parkinson's disease; ALS,increased,8858002,86,38,14,,Guam ALS/parkinsonism-dementia complex,MAPT_HUMAN(T231),DP0000254
Parkinson's disease,decreased; increased,17906618,4,0,1,,hyperphosphorylation in Parkinsons disease brains; hypophosphorylation in Parkinson's disease brains carrying C575R and Y431H mutations ,HTRA2_HUMAN(S142),DP0000255
prostate cancer,increased,12900420,10,0,2,,high in the low grade (well differentiated) and decreased in high grade (poorly differentiated) prostate cancer ,CREB1_HUMAN(S129),DP0000256
prostate cancer,increased,12900420,245,4,61,9187; 4095; 9196; 9198; 14228; 14001,high in the low grade (well differentiated) and decreased in high grade (poorly differentiated) prostate cancer ,CREB1_HUMAN(S133),DP0000257
type 2 diabetes; Alzheimer's disease,increased,19659459,32,7,0,,,MAPT_HUMAN(S422),DP0000258
type 2 diabetes; Alzheimer's disease,increased,19659459,106,50,116,39357,,MAPT_HUMAN(S202),DP0000259
type 2 diabetes; Alzheimer's disease,increased,19659459,105,48,69,91600; 35834; 20194; 98523,,MAPT_HUMAN(S404),DP0000260
type 2 diabetes; Alzheimer's disease,increased,19659459,84,20,2,,,MAPT_HUMAN(S262),DP0000261
type 2 diabetes; Alzheimer's disease,increased,19659459,20,26,6,,,MAPT_HUMAN(T217),DP0000262
type 2 diabetes; Alzheimer's disease,increased,19659459,70,27,33,29957,,MAPT_HUMAN(S199),DP0000263
type 2 diabetes; Alzheimer's disease,increased,19659459,119,41,90,9632,,MAPT_HUMAN(S396),DP0000264
type 2 diabetes; Alzheimer's disease,increased,19659459,42,29,23,12885,,MAPT_HUMAN(T181),DP0000265
retinitis pigmentosa,mutation of site,17932117,1,0,0,,retinitis pigmentosa type 18 (RP18);  T494M mutation,PRPF3_HUMAN(T494),DP0000266
Parkinson's disease,mutation of site,17890097,1,0,0,,patient with S125C mutation,NR4A2_HUMAN(S125),DP0000267
non-small cell lung cancer,increased,19002495,43,6,12,2235,Mutations in EGFR in NSCLC patients affect Y1016 and Y1197 phosphorylation. ,EGFR_HUMAN(Y1016),DP0000268
non-small cell lung cancer,increased,19002495,84,56,1028,2244; 4407,Mutations in EGFR in NSCLC patients affect Y1016 and Y1197 phosphorylation. ,EGFR_HUMAN(Y1197),DP0000269
Alzheimer's disease,increased,9832145,5,11,0,15013,,MAPT_HUMAN(S416),DP0000270
Alzheimer's disease,increased,9832145,2,4,1,,,MAPT_HUMAN(S185),DP0000271
Alzheimer's disease,increased,9832145,13,39,70,91600; 35834; 20194; 98523,,MAPT_HUMAN(S400),DP0000272
Alzheimer's disease,increased,9832145,2,5,1,,,MAPT_HUMAN(S238),DP0000273
Alzheimer's disease,increased,9832145,1,6,2,,,MAPT_HUMAN(T414),DP0000274
Alzheimer's disease,increased,9832145,2,9,1,,,MAPT_HUMAN(S237),DP0000275
Alzheimer's disease,increased,9832145,24,21,0,,,MAPT_HUMAN(S356),DP0000276
Alzheimer's disease,increased,9832145,37,13,5,,,MAPT_HUMAN(T212),DP0000277
Alzheimer's disease,increased,9832145,84,20,2,,,MAPT_HUMAN(S262),DP0000278
Alzheimer's disease,increased,9832145,5,27,26,91600; 35834; 20194; 98523,,MAPT_HUMAN(T403),DP0000279
Alzheimer's disease,increased,9832145,20,26,6,,,MAPT_HUMAN(T217),DP0000280
Alzheimer's disease,increased,9832145,105,48,69,91600; 35834; 20194; 98523,,MAPT_HUMAN(S404),DP0000281
Alzheimer's disease,increased,9832145,106,50,116,39357,,MAPT_HUMAN(S202),DP0000282
Alzheimer's disease,increased,9832145,4,6,34,,,MAPT_HUMAN(Y197),DP0000283
Alzheimer's disease,increased,9832145,119,41,90,9632,,MAPT_HUMAN(S396),DP0000284
Alzheimer's disease,increased,9832145,86,38,14,,,MAPT_HUMAN(T231),DP0000285
Alzheimer's disease,increased,9832145,2,5,0,,,MAPT_HUMAN(S210),DP0000286
Alzheimer's disease,increased,9832145,8,8,0,,,MAPT_HUMAN(T175),DP0000287
Alzheimer's disease,increased,9832145,13,9,5,,,MAPT_HUMAN(S409),DP0000288
Alzheimer's disease,increased,9832145,39,33,25,,,MAPT_HUMAN(S235),DP0000289
Alzheimer's disease,increased,9832145,19,13,10,,,MAPT_HUMAN(S198),DP0000290
Alzheimer's disease,increased,9832145,1,7,3,,,MAPT_HUMAN(S412),DP0000291
Alzheimer's disease,increased,9832145,46,19,42,77348,,MAPT_HUMAN(S214),DP0000292
Alzheimer's disease,increased,9832145,3,4,0,,,MAPT_HUMAN(S184),DP0000293
Alzheimer's disease,increased,9832145,42,29,23,12885,,MAPT_HUMAN(T181),DP0000294
Alzheimer's disease,increased,9832145,4,6,1,,,MAPT_HUMAN(S413),DP0000295
Alzheimer's disease,increased,9832145,70,27,33,29957,,MAPT_HUMAN(S199),DP0000296
lung cancer,increased,17483322,1,0,0,,,CDCA8_HUMAN(T278),DP0000297
lung cancer,increased,17483322,1,1,0,,,CDCA8_HUMAN(S275),DP0000298
ovarian cancer,increased,19940129,3,0,0,,,STK4_HUMAN(T120),DP0000299
ovarian cancer,decreased,19940129,16,1,5,3681; 49332,,STK4_HUMAN(T183),DP0000300
colorectal cancer,increased,20133777,4,48,1343,,dephosphorylation of PXN Y88 is tumor suppressive,PXN_HUMAN(Y88),DP0000301
psoriasis,increased,19663871,115,34,91,2855; 3929; 5123; 7547; 9459; 2846; 4923; 45613,"in lesional, but not in nonlesional, plaque-type psoriatic skin",EIF4EBP1_HUMAN(T46),DP0000302
psoriasis,increased,19663871,114,42,88,2855; 3929; 5123; 7547; 9459; 2846; 4923; 45613,"in lesional, but not in nonlesional, plaque-type psoriatic skin",EIF4EBP1_HUMAN(T37),DP0000303
Alzheimer's disease,increased,19889641,42,5,0,23706,Lewybody disease,SNCA_HUMAN(S129),DP0000304
pancreatic cancer,,19901077,4,1,1,,,RALA_HUMAN(S194),DP0000305
Huntington's disease,decreased,20064390,12,0,0,,,HTT_HUMAN(S16),DP0000306
Huntington's disease,decreased,20064390,12,1,0,,,HTT_HUMAN(S13),DP0000307
colorectal cancer,decreased,20122401,1,1,0,,,RORA_HUMAN(S35),DP0000308
hepatitis B,increased,20334631,16,12,14,,,KRT18_HUMAN(S53),DP0000309
hepatitis B,increased,20334631,14,26,13,,,KRT18_HUMAN(S34),DP0000310
sickle-cell anaemia,increased,20206558,1,5,46,,,EPB41_HUMAN(Y13),DP0000311
Parkinson's disease,increased,17610816,1,1,0,,,PRDX2_HUMAN(T89),DP0000312
ovarian cancer,increased,19876919,14,26,19,,,PAK1_HUMAN(T212),DP0000313
Alzheimer's disease,increased,19821112,37,13,5,,,MAPT_HUMAN(T212),DP0000314
breast cancer,increased,17254967,7,0,0,,,CDKN1B_HUMAN(Y74),DP0000315
breast cancer,increased,17697330,26,23,30,2405,Only in HER-2/neu positive tumors,HSPB1_HUMAN(S78),DP0000316
type 2 diabetes,increased,17709744,9,36,122,2385,,IRS1_HUMAN(S1101),DP0000317
type 2 diabetes,increased,17709744,367,6,1,9209; 9206; 97596; 9234; 9205,,RPS6KB1_HUMAN(T412),DP0000318
breast cancer,increased,17545609,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000319
ovarian cancer,increased,10822383,20,8,55,88106; 9271; 3787; 4060; 5315; 9563; 4070; 15116; 4051; 5102; 4075; 5012; 4071; 8599; 4058; 11962; 2336; 2337; 12694,,AKT2_HUMAN(S474),DP0000320
Alzheimer's disease,decreased,16606369,32,7,0,,"The tangles associated with Alzheimer's disease are correlated with a loss of phosphorylation at S422 in those cells.  However, phosphorylation of S422 appears to precede the cleavage event and may serve to protect Tau from cleavage.",MAPT_HUMAN(S422),DP0000321
ataxia-telangiectasia,decreased,9168116,2,0,0,,,ABL1_HUMAN(S446),DP0000322
Alzheimer's disease,increased,18208556,64,0,0,,,PPP2CA_HUMAN(Y307),DP0000323
Alzheimer's disease,increased,10757975,7,31,17,,,DPYSL2_HUMAN(S518),DP0000324
Alzheimer's disease,increased,10757975,20,47,84,,,DPYSL2_HUMAN(S522),DP0000325
Alzheimer's disease,increased,10757975,11,62,34,,,DPYSL2_HUMAN(T509),DP0000326
Wilm's tumor,increased,16799645,84,30,90,8826; 9177,,STAT1_HUMAN(S727),DP0000327
Parkinson's disease,increased,18371080,19,0,0,,,WWOX_HUMAN(Y33),DP0000328
neuroblastoma,increased,17234785,585,11,18,43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038,,AKT1_HUMAN(T308),DP0000329
neuroblastoma,increased,17234785,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000330
medullary thyroid carcinoma,increased,17209045,1126,149,4003,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,in tumors with activated RET (S891A allele),MAPK1_HUMAN(Y187),DP0000331
medullary thyroid carcinoma,increased,17209045,145,53,67,9134; 87544; 58978; 9136; 49081; 71958; 34911; 94994,in tumors with activated RET (S891A allele),STAT3_HUMAN(S727),DP0000332
medullary thyroid carcinoma,increased,17209045,1177,129,3549,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,in tumors with activated RET (S891A allele),MAPK3_HUMAN(Y204),DP0000333
medullary thyroid carcinoma,increased,17209045,1104,117,2416,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,in tumors with activated RET (S891A allele),MAPK1_HUMAN(T185),DP0000334
medullary thyroid carcinoma,increased,17209045,1154,100,2017,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,in tumors with activated RET (S891A allele),MAPK3_HUMAN(T202),DP0000335
glioblastoma multiforme,increased,18487454,1,2,20,,,AGAP2_HUMAN(S279),DP0000336
prostate cancer,increased,15580310,19,0,0,,,WWOX_HUMAN(Y33),DP0000337
"obesity, hyperphagic",mutation of site,15494731,11,0,49,4621,"hyperphagic, early-onset obesity",NTRK2_HUMAN(Y706),DP0000338
acute myelogenous leukemia,increased,18559500,4,2,0,,,ACIN1_HUMAN(S1180),DP0000339
prostate cancer,decreased; mutation of site,11980664,1,0,0,,polymorphism disturbs PKC consensus motif,NKX3-1_HUMAN(S48),DP0000340
DSPS,mutation of site,12736803,1,0,0,,,AANAT_HUMAN(T129),DP0000341
SLE,,12548559,2,0,1,,recognized by antibodies from lupus patients,SNRNP70_HUMAN(S140),DP0000342
type 2 diabetes,,17698598,15,1,0,,,GYS1_HUMAN(S8),DP0000343
type 2 diabetes,,17698598,31,27,2,47043; 3891,,GYS1_HUMAN(S641),DP0000344
type 2 diabetes,,17698598,21,31,7,,,GYS1_HUMAN(S645),DP0000345
type 2 diabetes,,17698598,9,2,1,,,GYS1_HUMAN(S11),DP0000346
Marfan syndrome,increased,15731757,36,0,5,18338; 3108; 26945; 55041; 11979; 8828; 68550; 56532,,SMAD2_HUMAN(S467),DP0000347
Marfan syndrome,increased,15731757,36,0,5,18338; 3108; 26945; 55041; 11979; 8828; 68550; 56532,,SMAD2_HUMAN(S465),DP0000348
acute myelogenous leukemia,mutation of site,15345593,5,2,76,4577,,FLT3_HUMAN(Y842),DP0000349
Alzheimer's disease,increased,12614922,42,29,23,12885,,MAPT_HUMAN(T181),DP0000350
breast cancer,increased,17599043,13,44,86,,,RB1_HUMAN(S249),DP0000351
breast cancer,increased,17599043,15,22,68,,,RB1_HUMAN(T252),DP0000352
pancreatic carcinoma,increased,18519681,321,70,3065,9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075,,STAT3_HUMAN(Y705),DP0000353
acute myelogenous leukemia,increased,18056483,346,100,3046,70926; 6943; 2101,,SRC_HUMAN(Y419),DP0000354
acute myelogenous leukemia,increased,18056483,46,56,9,9455; 13396,,EIF4EBP1_HUMAN(T70),DP0000355
acute myelogenous leukemia,increased,18056483,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000356
SLE,decreased,18714041,1,1,0,,,ELF1_HUMAN(T231),DP0000357
Alzheimer's disease,decreased,15033922,413,40,227,9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558,,GSK3B_HUMAN(S9),DP0000358
colorectal cancer,,15958584,86,17,427,3284,,PTK2_HUMAN(Y925),DP0000359
colorectal cancer,,15958584,68,21,307,,,PTK2_HUMAN(Y861),DP0000360
colorectal cancer,,15958584,346,100,3046,70926; 6943; 2101,,SRC_HUMAN(Y419),DP0000361
RIDDLE syndrome,increased,17940005,41,19,69,3001,in irradiated fibroblasts ,NBN_HUMAN(S343),DP0000362
RIDDLE syndrome,increased,17940005,19,14,67,,in irradiated fibroblasts ,SMC1A_HUMAN(S966),DP0000363
Huntington's disease,decreased,18772195,10,28,21,,phosphorylation decreased in HD; experimental phosphorylation restores defects in function,HTT_HUMAN(S419),DP0000364
RIDDLE syndrome,increased,17940005,167,22,4,13050; 4526; 5883,in irradiated fibroblasts ,ATM_HUMAN(S1981),DP0000365
RIDDLE syndrome,increased,17940005,3,0,1,2675,in irradiated fibroblasts ,TP53BP1_HUMAN(S1778),DP0000366
RIDDLE syndrome,decreased,17940005,144,3,12,2341; 12268; 2348,in irradiated fibroblasts,CHEK1_HUMAN(S345),DP0000367
infertility,mutation of site,19553676,1,0,0,,Y235C mutation causes hypergonadotropic ovarian failure,BMP15_HUMAN(Y235),DP0000368
Alzheimer's disease,increased,15883264,86,38,14,,,MAPT_HUMAN(T231),DP0000369
astrocytoma,decreased,19761816,4,0,0,,,AQP4_HUMAN(S180),DP0000370
ovarian cancer,increased,19876919,7,11,100,2607,,PAK2_HUMAN(S20),DP0000371
ovarian cancer,increased,19876919,33,3,11,2601,,PAK1_HUMAN(T423),DP0000372
Alzheimer's disease,increased,19821112,86,38,14,,,MAPT_HUMAN(T231),DP0000373
Alzheimer's disease,increased,19821112,39,33,25,,,MAPT_HUMAN(S235),DP0000374
Alzheimer's disease,increased,19821112,46,19,42,77348,,MAPT_HUMAN(S214),DP0000375
acute myelogenous leukemia,increased,19805619,6,1,0,,,CSF2RB_HUMAN(S601),DP0000376
ovarian cancer,increased,17001009,5,62,12,9164,,JUND_HUMAN(S100),DP0000377
ovarian cancer,increased,17001009,0,5,1,,,PLEKHA6_HUMAN(S455),DP0000378
ovarian cancer,increased,17001009,68,3,2,4270; 2009; 13537; 9561,,CTNNB1_HUMAN(S33),DP0000379
ovarian cancer,increased,17001009,1,22,3,,,SYNM_HUMAN(S429),DP0000380
ovarian cancer,increased,17001009,1,18,0,,,TNS3_HUMAN(S1441),DP0000381
ovarian cancer,increased,17001009,2,42,0,,,IRS2_HUMAN(S1100),DP0000382
ovarian cancer,increased,17001009,0,1,1,,,RIPOR1_HUMAN(S453),DP0000383
ovarian cancer,increased,17001009,73,64,16,8752; 9164; 3270; 12714,,JUN_HUMAN(S73),DP0000384
melanoma skin cancer,increased,17001009,0,21,1,,,USP10_HUMAN(S547),DP0000385
melanoma skin cancer,increased,17001009,73,64,16,8752; 9164; 3270; 12714,,JUN_HUMAN(S73),DP0000386
melanoma skin cancer,increased,17001009,0,1,1,,,RIPOR1_HUMAN(S453),DP0000387
melanoma skin cancer,increased,17001009,0,10,11,,,RPS17_HUMAN(S115),DP0000388
melanoma skin cancer,increased,17001009,5,62,12,9164,,JUND_HUMAN(S100),DP0000389
melanoma skin cancer,increased,17001009,1,18,0,,,TNS3_HUMAN(S1441),DP0000390
melanoma skin cancer,increased,17001009,0,3,10,,,TAF13_HUMAN(S33),DP0000391
melanoma skin cancer,increased,17001009,1,22,3,,,SYNM_HUMAN(S429),DP0000392
melanoma skin cancer,increased,17001009,68,3,2,4270; 2009; 13537; 9561,,CTNNB1_HUMAN(S33),DP0000393
melanoma skin cancer,increased,17001009,2,42,0,,,IRS2_HUMAN(S1100),DP0000394
melanoma skin cancer,increased,17001009,0,5,15,,,BCAR3_HUMAN(T130),DP0000395
breast cancer,increased,19940281,81,2,0,2511,High S118 ER-alpha phosphorylation is found in some breast cancer tumors. ,ESR1_HUMAN(S118),DP0000396
sickle-cell anaemia,increased,20206558,1,1,0,,,SPTA1_HUMAN(Y1499),DP0000397
sickle-cell anaemia,increased,20206558,1,1,0,,,SPTA1_HUMAN(Y548),DP0000398
sickle-cell anaemia,increased,20206558,1,1,0,,,SPTA1_HUMAN(Y422),DP0000399
ovarian cancer,increased,20227043,19,10,125,2842; 4791,,ERBB3_HUMAN(Y1289),DP0000400
ovarian cancer,decreased,20153512,585,11,18,43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038,phosphorylated in a majority of tumor specimens,AKT1_HUMAN(T308),DP0000401
prostate cancer,increased,20406887,9,46,145,14143,,ARHGEF2_HUMAN(S885),DP0000402
Fetal growth restriction,increased,20143870,11,8,0,,,IGFBP1_HUMAN(S126),DP0000403
Fetal growth restriction,increased,20143870,11,12,0,,,IGFBP1_HUMAN(S194),DP0000404
Fetal growth restriction,increased,20143870,5,7,0,,,IGFBP1_HUMAN(S123),DP0000405
pancreatic carcinoma,increased,20455595,2,31,0,,presence of autoantibodies directed against phosphorylated S419 in patients with pancreatic cancer,ENO1_HUMAN(S419),DP0000406
acute lymphocytic leukemia; acute myelogenous leukemia; chronic myelogenous leukemia,increased,20508164,9,24,0,,phosphorylation of this site was not detected in bone marrow samples obtained from healthy donors,STAT5A_HUMAN(S780),DP0000407
adrenocortical carcinoma,increased,20484036,130,14,106,2971; 5536; 2976,mTor signaling is activated in ACT (childhood adrenocortical tumors); S2448 phosphorylation is expressed during mitosis,MTOR_HUMAN(S2448),DP0000408
adrenocortical carcinoma,increased,20484036,68,32,561,13020; 5044; 9468; 14236; 5018; 2215; 5364,mTor signaling is activated in ACT (childhood adrenocortical tumors); S2448 phosphorylation is expressed during mitosis,RPS6_HUMAN(S244),DP0000409
adrenocortical carcinoma,increased,20484036,68,66,847,13020; 5044; 9468; 14236; 5018; 2215; 5364,mTor signaling is activated in ACT (childhood adrenocortical tumors); S2448 phosphorylation is expressed during mitosis,RPS6_HUMAN(S240),DP0000410
glioblastoma,increased,20455003,321,70,3065,9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075,Y705 phosphorylation is a prognostic factor for survival (patients with higher levels had shorter overall survival than those with lower levels),STAT3_HUMAN(Y705),DP0000411
tuberous sclerosis,increased,17671177,68,32,561,13020; 5044; 9468; 14236; 5018; 2215; 5364,,RPS6_HUMAN(S244),DP0000412
tuberous sclerosis,increased,17671177,1104,117,2416,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK1_HUMAN(T185),DP0000413
tuberous sclerosis,increased,17671177,1177,129,3549,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK3_HUMAN(Y204),DP0000414
tuberous sclerosis,increased,17671177,1126,149,4003,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK1_HUMAN(Y187),DP0000415
tuberous sclerosis,increased,17671177,68,66,847,13020; 5044; 9468; 14236; 5018; 2215; 5364,,RPS6_HUMAN(S240),DP0000416
tuberous sclerosis,increased,17671177,1154,100,2017,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK3_HUMAN(T202),DP0000417
colorectal carcinoma,increased,16619028,8,3,35,,,CASP8_HUMAN(Y380),DP0000418
spinocerebellar ataxia type 14,decreased,15964845,2,14,2,,"missense mutations of PKCG associated with familial SCA14 decrease phosphorylation of T514, T655, T674.",PRKCG_HUMAN(T655),DP0000419
spinocerebellar ataxia type 14,decreased,15964845,4,44,45,9379; 2060; 38938,"missense mutations of PKCG associated with familial SCA14 decrease phosphorylation of T514, T655, T674.",PRKCG_HUMAN(T514),DP0000420
spinocerebellar ataxia type 14,decreased,15964845,3,3,1,,"missense mutations of PKCG associated with familial SCA14 decrease phosphorylation of T514, T655, T674.",PRKCG_HUMAN(T674),DP0000421
pulmonary emphysema,increased,14764579,1154,100,2017,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK3_HUMAN(T202),DP0000422
pulmonary emphysema,increased,14764579,1177,129,3549,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK3_HUMAN(Y204),DP0000423
pulmonary emphysema,increased,14764579,1104,117,2416,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK1_HUMAN(T185),DP0000424
pulmonary emphysema,increased,14764579,1126,149,4003,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK1_HUMAN(Y187),DP0000425
"cancer, squamous cell carcinoma",increased,14603053,281,31,474,8556; 3283,"FAK pY397 was more nuclear; however, little correlation between pY397 and tumor differentiation",PTK2_HUMAN(Y397),DP0000426
colorectal cancer,decreased,12871985,27,13,139,,"pY407 and pY397 of FAK decrease as tumors go from well differentiated to poorly (correlation r=0.9).  No correlation with pY576, pY577, pY861, and pY925 and tumor differentiation.",PTK2_HUMAN(Y407),DP0000427
colorectal cancer,decreased,12871985,281,31,474,8556; 3283,"pY407 and pY397 of FAK decrease as tumors go from well differentiated to poorly (correlation r=0.9).  No correlation with pY576, pY577, pY861, and pY925 and tumor differentiation.",PTK2_HUMAN(Y397),DP0000428
breast cancer,increased,12753909,7,3,21,,"HER2(+) breast cancer.  Strong pY216, modest  pY419.",SRC_HUMAN(Y216),DP0000429
breast cancer,increased,12753909,346,100,3046,70926; 6943; 2101,"HER2(+) breast cancer.  Strong pY216, modest  pY419.",SRC_HUMAN(Y419),DP0000430
spinocerebellar ataxia type 1,increased,12741986,16,25,3,,,ATXN1_HUMAN(S775),DP0000431
Alzheimer's disease,increased,16705182,36,5,3,6986; 3823,,APP_HUMAN(T668),DP0000432
non-small cell large cell lung carcinoma; non-small cell squamous cell lung carcinoma,increased,16505275,77,19,171,2231; 6963,,EGFR_HUMAN(Y869),DP0000433
rhabdomyosarcoma,mutation of site,11850543,1,8,5,,,KRT8_HUMAN(S291),DP0000434
hepatocellular carcinoma,increased,16936701,77,19,171,2231; 6963,,EGFR_HUMAN(Y869),DP0000435
acute myelogenous leukemia,mutation of site,17105820,14,0,0,3474; 3466; 3461; 3464,duplication of site,FLT3_HUMAN(Y591),DP0000436
Alzheimer's disease,increased,11034902,119,41,90,9632,Antibodies to phosphorylated  S396/404 stain brain sections early in the disease. ,MAPT_HUMAN(S396),DP0000437
kidney cancer,increased,12649200,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000438
breast cancer,increased,17967179,346,100,3046,70926; 6943; 2101,in selected cell lines,SRC_HUMAN(Y419),DP0000439
breast cancer,increased,17967179,321,70,3065,9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075,in selected cell lines,STAT3_HUMAN(Y705),DP0000440
non-small cell lung cancer,increased,17653080,77,19,171,2231; 6963,,EGFR_HUMAN(Y869),DP0000441
Alzheimer's disease,increased,15652175,84,20,2,,,MAPT_HUMAN(S262),DP0000442
esophageal carcinoma,mutation of site,18598945,2,36,0,,,FBXO4_HUMAN(S12),DP0000443
Burkitt's lymphoma,mutation of site,10713166,56,37,30,46650,,MYC_HUMAN(T58),DP0000444
Emery-Dreifuss muscular dystrophy,mutation of site,18808171,4,46,106,,,LMNA_HUMAN(S404),DP0000445
colorectal carcinoma,increased,12234980,213,13,1,3458; 5764; 53348; 29237; 9701; 3465; 8481; 8552; 9711; 3642; 9706; 3377; 9606; 3475,,HIST1H3A_HUMAN(S10),DP0000446
intraocular melanoma,increased,10969768,62,38,80,8974; 8957; 8516; 4277; 9308; 11917,,RB1_HUMAN(S811),DP0000447
intraocular melanoma,increased,10969768,63,43,112,8974; 8957; 8516; 4277; 9308; 11917,,RB1_HUMAN(S807),DP0000448
acute myelogenous leukemia,duplication,9305596,14,0,0,3474; 3466; 3461; 3464,,FLT3_HUMAN(Y591),DP0000449
colorectal cancer,,19115206,26,8,9,,,KRT8_HUMAN(S74),DP0000450
colorectal cancer,,19115206,26,8,23,,,KRT8_HUMAN(S432),DP0000451
bladder cancer,increased,18939995,321,70,3065,9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075,,STAT3_HUMAN(Y705),DP0000452
Alzheimer's disease,increased,18725412,74,21,26,43964; 49561; 53001,,MAPT_HUMAN(T205),DP0000453
Alzheimer's disease,increased,18725412,105,48,69,91600; 35834; 20194; 98523,,MAPT_HUMAN(S404),DP0000454
Alzheimer's disease,increased,18725412,119,41,90,9632,,MAPT_HUMAN(S396),DP0000455
Alzheimer's disease,increased,18725412,70,27,33,29957,,MAPT_HUMAN(S199),DP0000456
Alzheimer's disease,increased,18725412,46,19,42,77348,,MAPT_HUMAN(S214),DP0000457
Alzheimer's disease,increased,18725412,37,13,5,,,MAPT_HUMAN(T212),DP0000458
Alzheimer's disease,increased,18725412,106,50,116,39357,,MAPT_HUMAN(S202),DP0000459
Alzheimer's disease,increased,15652175,3,0,0,,,MAPT_HUMAN(S320),DP0000460
acute myelogenous leukemia,duplication,9305596,7,0,2,,,FLT3_HUMAN(Y599),DP0000461
Alzheimer's disease,increased,11034902,105,48,69,91600; 35834; 20194; 98523,Antibodies to phosphorylated  S396/404 stain brain sections early in the disease. ,MAPT_HUMAN(S404),DP0000462
ovarian cancer,increased,20009884,118,2,0,9287,"In p53-positive ovarian carinomas, S392 phosphorylation was associated with advanced tumor stage and high tumor grade. S20 phosphorylation was associated with low tumor grade in p53-positive, and high tumor grade in p53-negative, ovarian carcinomas.",TP53_HUMAN(S20),DP0000463
ovarian cancer,increased,20009884,95,14,0,9281,"In p53-positive ovarian carinomas, S392 phosphorylation was associated with advanced tumor stage and high tumor grade. S20 phosphorylation was associated with low tumor grade in p53-positive, and high tumor grade in p53-negative, ovarian carcinomas.",TP53_HUMAN(S392),DP0000464
type 2 diabetes,increased,20012595,0,5,1,,22% increase in patients with type II diabetes; 37% increase in obese non-diabetic patients,ATP5B_HUMAN(T213),DP0000465
type 2 diabetes,increased,20012595,0,1,13,,32% increase in obese non-diabetic patients and patients with type II diabetes,ATP5B_HUMAN(Y361),DP0000466
"cancer, squamous cell carcinoma",increased,19934324,20,92,3048,70926; 6943; 2101,,FYN_HUMAN(Y420),DP0000467
breast cancer,increased,19956839,45,17,0,9713,"mTOR S2481 phosphorylation is useful to determine mitotic activity index (MAI), as a proliferation-associated prognostic factor for breast cancer patients.",HIST1H3A_HUMAN(S28),DP0000468
breast cancer,increased,19956839,52,27,1,2974,"mTOR S2481 phosphorylation is useful to determine mitotic activity index (MAI), as a proliferation-associated prognostic factor for breast cancer patients.",MTOR_HUMAN(S2481),DP0000469
breast cancer,increased,19956839,213,13,1,3458; 5764; 53348; 29237; 9701; 3465; 8481; 8552; 9711; 3642; 9706; 3377; 9606; 3475,"mTOR S2481 phosphorylation is useful to determine mitotic activity index (MAI), as a proliferation-associated prognostic factor for breast cancer patients.",HIST1H3A_HUMAN(S10),DP0000470
Alzheimer's disease,increased,20110615,2,14,33,,,MAPT_HUMAN(Y394),DP0000471
Alzheimer's disease,increased,20110615,119,41,90,9632,,MAPT_HUMAN(S396),DP0000472
hepatocellular carcinoma,increased,20224721,139,4,0,4887; 3036; 5733; 3031; 4886; 4025; 3033; 13346,"fibrolamellar hepatocellular carcinoma.  high levels of phosphorylation in 88% of fibrolamellar hepatocellular carcinoma sample, 10% of normal liver samples.",RELA_HUMAN(S536),DP0000473
LVR; MI,decreased,20418543,9,0,0,,,TNNT2_HUMAN(S208),DP0000474
Alzheimer's disease; ALS,increased,19046355,8,8,0,,T175 phosphorylation induced increased fibril formation in ALS patient samples with cognitive impairment.,MAPT_HUMAN(T175),DP0000475
colorectal cancer,increased,20530691,2,22,23,,,TNIK_HUMAN(S764),DP0000476
prostate cancer,increased,20623637,6,27,235,3138,correlates positively with disease progression and negatively with survival of patients,TNK2_HUMAN(Y284),DP0000477
Alzheimer's disease,increased,20624930,3,28,24,,,NEFM_HUMAN(S620),DP0000478
Alzheimer's disease,increased,20624930,0,10,0,,,NEFM_HUMAN(S672),DP0000479
Alzheimer's disease,increased,20624930,0,16,3,,,NEFM_HUMAN(S685),DP0000480
Alzheimer's disease,increased,20624930,0,4,3,,,NEFM_HUMAN(S788),DP0000481
Alzheimer's disease,increased,20624930,0,14,2,,,NEFM_HUMAN(S646),DP0000482
Alzheimer's disease,increased,20624930,1,19,0,,,NEFM_HUMAN(S837),DP0000483
Alzheimer's disease,increased,20624930,0,11,3,,,NEFM_HUMAN(S783),DP0000484
Alzheimer's disease,increased,20624930,0,10,2,,,NEFM_HUMAN(S667),DP0000485
Alzheimer's disease,increased,20624930,4,23,1,,,NEFM_HUMAN(S736),DP0000486
Alzheimer's disease,increased,20624930,0,14,2,,,NEFM_HUMAN(S659),DP0000487
Alzheimer's disease,increased,20624930,0,13,0,,,NEFM_HUMAN(S680),DP0000488
Alzheimer's disease,increased,20624930,4,19,19,,,NEFM_HUMAN(S615),DP0000489
Alzheimer's disease,increased,20624930,0,14,0,,,NEFM_HUMAN(S641),DP0000490
Alzheimer's disease,increased,20624930,0,11,0,,,NEFH_HUMAN(S801),DP0000491
Alzheimer's disease,increased,20624930,0,8,0,,,NEFH_HUMAN(S716),DP0000492
Alzheimer's disease,increased,20624930,0,8,5,,,NEFH_HUMAN(S648),DP0000493
Alzheimer's disease,increased,20624930,0,8,0,,,NEFH_HUMAN(S744),DP0000494
Alzheimer's disease,increased,20624930,0,8,4,,,NEFH_HUMAN(S640),DP0000495
Alzheimer's disease,increased,20624930,0,13,0,,,NEFH_HUMAN(S546),DP0000496
Alzheimer's disease,increased,20624930,0,15,0,,,NEFH_HUMAN(S710),DP0000497
Alzheimer's disease,increased,20624930,0,15,4,,,NEFH_HUMAN(S580),DP0000498
Alzheimer's disease,increased,20624930,0,15,9,,,NEFH_HUMAN(S702),DP0000499
Alzheimer's disease,increased,20624930,0,12,6,,,NEFH_HUMAN(S620),DP0000500
"cancer, squamous cell carcinoma",increased,20713986,12,12,0,,,FSCN1_HUMAN(S39),DP0000501
breast cancer,increased,20855525,6,0,1,,,ITGB4_HUMAN(Y1494),DP0000502
breast cancer,increased,20855525,20,92,3048,70926; 6943; 2101,,FYN_HUMAN(Y420),DP0000503
glioblastoma multiforme,increased,19573808,4,32,171,6347,high levels in grade IV astrocytomas (GBM),EPHA2_HUMAN(S897),DP0000504
ovarian epithelial carcinoma,increased,21276607,130,14,106,2971; 5536; 2976,,MTOR_HUMAN(S2448),DP0000505
ovarian epithelial carcinoma,increased,21276607,114,42,88,2855; 3929; 5123; 7547; 9459; 2846; 4923; 45613,,EIF4EBP1_HUMAN(T37),DP0000506
ovarian epithelial carcinoma,increased,21276607,367,6,1,9209; 9206; 97596; 9234; 9205,,RPS6KB1_HUMAN(T412),DP0000507
ovarian epithelial carcinoma,increased,21276607,115,34,91,2855; 3929; 5123; 7547; 9459; 2846; 4923; 45613,,EIF4EBP1_HUMAN(T46),DP0000508
colonic inflamation,increased,20580720,15,59,9,9566; 5651,"chronic ulcerative colitis (CUC), ulcerative colitis associated dysplasia (UCD), colitis-associated cancer (CAC)",CTNNB1_HUMAN(S552),DP0000509
SLE,decreased,21097497,5,16,0,,,SP1_HUMAN(S59),DP0000510
B cell lymphoma,mutation of site,21349429,4,0,0,,,RAG2_HUMAN(T490),DP0000511
scleroderma,increased,21321929,6,0,0,,,FLI1_HUMAN(T312),DP0000512
VHL,mutation of site,22071692,1,0,1,,patient-derived S111 mutations cause the loss of tumor suppressor function in VHL; ,VHL_HUMAN(S111),DP0000513
prostate cancer,increased,21799006,15,1,0,,xenografts ,AR_HUMAN(S83),DP0000514
SLE,increased,21983831,14,6,23,9379; 9377; 2060; 38938,activation of the KHS2-PKCT-IKK pathway controls SLE pathogenesis,PRKCQ_HUMAN(T538),DP0000515
lung cancer,decreased,21060948,78,30,180,13008; 29495; 4911; 57706,,YAP1_HUMAN(S127),DP0000516
hepatocellular carcinoma,increased,22196886,1,1,0,,,FOXA2_HUMAN(S111),DP0000517
hepatocellular carcinoma,increased,22196886,1,1,0,,,FOXA2_HUMAN(S107),DP0000518
chronic myelogenous leukemia,increased,12124177,14,30,1018,3901,,BCR_HUMAN(Y177),DP0000519
breast cancer,increased,20231902,2,0,1,,,STK3_HUMAN(T117),DP0000520
acute lymphocytic leukemia; acute myelogenous leukemia; B cell lymphoma,increased,22442148,2,18,1,,constitutive phosphorylation of this site was observed,STAT5B_HUMAN(S193),DP0000521
glioblastoma,increased,22056988,2,2,0,,,CTNNB1_HUMAN(Y333),DP0000522
hepatocellular carcinoma,increased,22153071,321,70,3065,9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075,,STAT3_HUMAN(Y705),DP0000523
prostate cancer,decreased,22511927,5,0,0,,,CTNNB1_HUMAN(T120),DP0000524
ataxia-telangiectasia,decreased,19876065,3,0,0,2674,,TP53BP1_HUMAN(S25),DP0000525
hepatocellular carcinoma,increased,20180147,281,31,474,8556; 3283,"Phosphorylated Y379 is overexpressed in hepaocellular carcinoma, and correlated with tumor stage, vascular invasion, and intrahepatic  metastasis, ",PTK2_HUMAN(Y397),DP0000526
breast cancer,increased,22052162,3,1,0,,,ATF4_HUMAN(S245),DP0000527
FTLD,increased,20886841,10,3,0,,,GFAP_HUMAN(S13),DP0000528
FTLD,decreased,20886841,0,25,31,,,MAP1A_HUMAN(S612),DP0000529
Huntington's disease,increased,22011578,99,3,0,2521,,TP53_HUMAN(S46),DP0000530
Alzheimer's disease,increased,21828286,0,1,0,,,MAP2_HUMAN(S1702),DP0000531
Alzheimer's disease,increased,21828286,86,38,14,,,MAPT_HUMAN(T231),DP0000532
Alzheimer's disease,increased,21828286,0,57,16,,,MAP1B_HUMAN(S1396),DP0000533
Alzheimer's disease,increased,21828286,3,4,0,,,MAPT_HUMAN(S184),DP0000534
Alzheimer's disease,increased,21828286,119,41,90,9632,,MAPT_HUMAN(S396),DP0000535
Alzheimer's disease,increased,21828286,4,23,1,,,NEFM_HUMAN(S736),DP0000536
Alzheimer's disease,increased,21828286,39,33,25,,,MAPT_HUMAN(S235),DP0000537
Alzheimer's disease,increased,21828286,42,29,23,12885,,MAPT_HUMAN(T181),DP0000538
Alzheimer's disease,increased,21828286,84,20,2,,,MAPT_HUMAN(S262),DP0000539
Alzheimer's disease,increased,21828286,20,26,6,,,MAPT_HUMAN(T217),DP0000540
Alzheimer's disease,increased,21828286,0,3,0,,,MAP2_HUMAN(S1706),DP0000541
Alzheimer's disease,increased,21828286,2,4,1,,,MAPT_HUMAN(S185),DP0000542
Alzheimer's disease,increased,21828286,0,1,1,,,NEFH_HUMAN(S948),DP0000543
Alzheimer's disease,increased,21828286,0,66,53,,,MAP1B_HUMAN(S1779),DP0000544
Alzheimer's disease,increased,21828286,0,65,24,,,MAP1B_HUMAN(S1400),DP0000545
Alzheimer's disease,increased,21828286,0,16,3,,,NEFM_HUMAN(S685),DP0000546
Alzheimer's disease,increased,21828286,37,13,5,,,MAPT_HUMAN(T212),DP0000547
Alzheimer's disease,increased,21828286,5,27,26,91600; 35834; 20194; 98523,,MAPT_HUMAN(T403),DP0000548
Alzheimer's disease,increased,21828286,0,1,0,,,NEFM_HUMAN(S33),DP0000549
breast cancer,increased,22566623,1,2,0,,,PIN1_HUMAN(S138),DP0000550
ventricular tachycardia,decreased,22653970,4,1,3,,phosphorylation of this site is decreased by T887H nsSNP  mutation in Kv11.1,KCNH2_HUMAN(S890),DP0000551
Parkinson's disease,increased,22344688,42,5,0,23706,"PD patients had higher S129 phosphorylation levels compared to healthy controls. Patients with multiple system atrophy (MSA) or progressive supranuclear palsy (PSP) patient, had lower S129 phosphorylation than PD patients or healthy controls. There was a weak correlation with P-S129 levels and severity of the PD.",SNCA_HUMAN(S129),DP0000552
DCM,decreased,22972900,51,7,16,4004,similar effect has been observed in ISHD (failing ischemic hearts),TNNI3_HUMAN(S24),DP0000553
DCM,decreased,22972900,0,3,1,,similar effect has been observed in ISHD (failing ischemic hearts),TNNI3_HUMAN(S5),DP0000554
DCM,decreased,22972900,55,7,11,4004,similar effect has been observed in ISHD (failing ischemic hearts),TNNI3_HUMAN(S23),DP0000555
DCM,decreased,22972900,0,4,1,,similar effect has been observed in ISHD (failing ischemic hearts),TNNI3_HUMAN(S6),DP0000556
DCM,decreased,22972900,1,2,7,,similar effect has been observed in ISHD (failing ischemic hearts),TNNI3_HUMAN(Y26),DP0000557
DCM,increased,22972900,0,2,0,,similar effect has been observed in ISHD (failing ischemic hearts),TNNI3_HUMAN(T78),DP0000558
DCM,increased,22972900,22,2,0,,similar effect has been observed in ISHD (failing ischemic hearts),TNNI3_HUMAN(S42),DP0000559
DCM,increased,22972900,2,2,0,,similar effect has been observed in ISHD (failing ischemic hearts),TNNI3_HUMAN(S77),DP0000560
DCM,increased,22972900,22,3,0,,similar effect has been observed in ISHD (failing ischemic hearts),TNNI3_HUMAN(S44),DP0000561
DCM,increased,22972900,0,1,0,,similar effect has been observed in ISHD (failing ischemic hearts),TNNI3_HUMAN(T181),DP0000562
DCM,increased,22972900,1,3,0,,similar effect has been observed in ISHD (failing ischemic hearts),TNNI3_HUMAN(S166),DP0000563
DCM,increased,22972900,27,2,1,,similar effect has been observed in ISHD (failing ischemic hearts),TNNI3_HUMAN(T143),DP0000564
DCM,increased,22972900,2,5,0,,similar effect has been observed in ISHD (failing ischemic hearts),TNNI3_HUMAN(S199),DP0000565
urethral cancer; brain cancer; colorectal cancer,increased,22975685,2,0,0,,,PHF20_HUMAN(S291),DP0000566
urethral cancer; brain cancer; colorectal cancer,increased,22975685,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000567
colorectal carcinoma,increased,23114923,6,0,1,,,ELK1_HUMAN(T417),DP0000568
lung cancer,increased,22266860,14,1,0,,,SP1_HUMAN(T739),DP0000569
"obesity, hyperphagic",decreased,18398140,31,10,2,4139,,LIPE_HUMAN(S853),DP0000570
"obesity, hyperphagic",decreased,18398140,7,4,4,,,LIPE_HUMAN(S950),DP0000571
"obesity, hyperphagic",decreased,18398140,23,26,1,4137,,LIPE_HUMAN(S855),DP0000572
psoriasis,increased,19663871,50,3,0,9741,"in lesional, but not in nonlesional, plaque-type psoriatic skin",EIF4E_HUMAN(S209),DP0000573
melanoma skin cancer,increased,23227340,1,15,23,,melanomas wiith metastatic potential,HIST1H3A_HUMAN(T80),DP0000574
rheumatoid arthritis,decreased,23396208,3,0,0,,,FOXP3_HUMAN(S418),DP0000575
diabetes mellitus,decreased,17272402,1177,129,3549,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK3_HUMAN(Y204),DP0000576
diabetes mellitus,decreased,17272402,1126,149,4003,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK1_HUMAN(Y187),DP0000577
diabetes mellitus,decreased,17272402,1104,117,2416,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK1_HUMAN(T185),DP0000578
diabetes mellitus,decreased,17272402,1154,100,2017,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,,MAPK3_HUMAN(T202),DP0000579
pancreatic carcinoma,decreased,18519681,145,53,67,9134; 87544; 58978; 9136; 49081; 71958; 34911; 94994,,STAT3_HUMAN(S727),DP0000580
non-small cell lung adenocarcinoma,decreased,18687633,52,15,200,2244; 2247,,ERBB2_HUMAN(Y1248),DP0000581
non-small cell lung adenocarcinoma,decreased,18687633,10,20,59,12428; 11971; 9576; 9516; 85553; 13820,,SMAD1_HUMAN(S465),DP0000582
non-small cell lung adenocarcinoma,decreased,18687633,34,7,4,3203; 3193; 2386,,IRS1_HUMAN(S616),DP0000583
non-small cell lung adenocarcinoma,decreased,18687633,38,18,117,2237,,EGFR_HUMAN(Y1069),DP0000584
non-small cell lung adenocarcinoma,decreased,18687633,10,13,58,12428; 11971; 9576; 9516; 85553; 13820,,SMAD1_HUMAN(S463),DP0000585
ovarian cancer,increased,23318434,2,0,0,,,MYC_HUMAN(Y74),DP0000586
prostate cancer,decreased,23945560,5,0,0,,high expression correlates with increased patient survival time from disease recurrence,AR_HUMAN(S792),DP0000587
prostate cancer,decreased,23945560,10,5,0,,high levels associated with greater patient survival time,AR_HUMAN(S310),DP0000588
non-small cell lung cancer,increased,23975372,3,1,0,,lymph node metastasis and advanced stages,ATF4_HUMAN(S245),DP0000589
Status epilepticus; CSWSS,mutation of site,23933820,5,1,13,,,GRIN2A_HUMAN(Y1387),DP0000590
CCM,mutation of site,24466005,1,1,0,,phosphorylation site,CCM2_HUMAN(S238),DP0000591
XLP,decreased,24688028,39,92,2957,70926; 6943; 2101,decrease upon restimulation of XLP patient T cells,LCK_HUMAN(Y394),DP0000592
Alzheimer's disease,increased,24886973,23,0,1,95697; 16177,neurofibrillary tangles are positive for S349,SQSTM1_HUMAN(S349),DP0000593
MPPH1,mutation of site,24705253,4,2,11,,,CCND2_HUMAN(T280),DP0000594
neurofibromatosis type 1,increased,23318430,321,70,3065,9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075,malignant peripheral nerve sheath tumors (MPNSTs),STAT3_HUMAN(Y705),DP0000595
glioblastoma multiforme,increased,25553095,5,1,0,,poor prognosis and overall survival,HIST1H3A_HUMAN(T6),DP0000596
glioblastoma multiforme,increased,25553095,213,13,1,3458; 5764; 53348; 29237; 9701; 3465; 8481; 8552; 9711; 3642; 9706; 3377; 9606; 3475,poor prognosis and overall survival,HIST1H3A_HUMAN(S10),DP0000597
multiple myeloma,increased,25660025,6,28,2,,,KIF11_HUMAN(T926),DP0000598
X-linked agammaglobulinaemia,increased,22366891,346,100,3046,70926; 6943; 2101,,SRC_HUMAN(Y419),DP0000599
X-linked agammaglobulinaemia,increased,22366891,79,62,2523,3281,,PTK2_HUMAN(Y576),DP0000600
X-linked agammaglobulinaemia,increased,22366891,73,38,1747,3281,,PTK2_HUMAN(Y577),DP0000601
X-linked agammaglobulinaemia,increased,22366891,16,48,1560,2731,,LYN_HUMAN(Y508),DP0000602
X-linked agammaglobulinaemia,increased,22366891,31,6,76,12081; 12967; 2711; 5514; 6485; 4349; 2710,,SYK_HUMAN(Y525),DP0000603
X-linked agammaglobulinaemia,increased,22366891,3,3,39,,,PIK3R1_HUMAN(Y508),DP0000604
X-linked agammaglobulinaemia,increased,22366891,18,1,0,,,VAV1_HUMAN(Y174),DP0000605
glioblastoma multiforme,increased,25553095,6,3,4,,poor prognosis and overall survival,HIST1H3A_HUMAN(Y41),DP0000606
mosaic variegated aneuploidy (MVA) syndrome,increased,25660017,1,0,0,,,KIF2A_HUMAN(T554),DP0000607
Alzheimer's disease,increased,25650666,2,0,1,,aggregates in human brain cortex,TRAPPC6A_HUMAN(S35),DP0000608
type 2 diabetes,decreased,15033922,413,40,227,9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558,,GSK3B_HUMAN(S9),DP0000609
breast ductal carcinoma,decreased,20832312,1,5,0,,,EEF1A1_HUMAN(S300),DP0000610
Down syndrome,increased,20696760,402,8,0,9235; 8695; 9284; 9286; 8514; 12571; 4030,,TP53_HUMAN(S15),DP0000611
type 2 diabetes,decreased,20938636,16,66,253,8730,,TBC1D4_HUMAN(S588),DP0000612
type 2 diabetes,decreased,20938636,12,16,334,8619,,TBC1D4_HUMAN(S318),DP0000613
type 2 diabetes,decreased,20938636,10,9,48,,,TBC1D4_HUMAN(S751),DP0000614
type 2 diabetes,decreased,20938636,585,11,18,43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038,insulin-stimulated phosphorylation,AKT1_HUMAN(T308),DP0000615
thymic carcinoma,increased,20597130,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,phosphorylation-positive patients show trend toward increased disease progression and poorer survival,AKT1_HUMAN(S473),DP0000616
Parkinson's disease,,21658387,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,Parkinson's disease associated mutations showed reduced interactions and phosphorylation of AKT1. ,AKT1_HUMAN(S473),DP0000617
Parkinson's disease,increased,21865317,42,5,0,23706,,SNCA_HUMAN(S129),DP0000618
SLE,increased,22230807,4,14,22,,,S100A9_HUMAN(T113),DP0000619
prostate cancer,increased,22197205,19,18,0,,,CALD1_HUMAN(S789),DP0000620
melanoma skin cancer,increased,19996208,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000621
melanoma skin cancer,increased,19996208,585,11,18,43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038,,AKT1_HUMAN(T308),DP0000622
melanoma skin cancer,increased,19996208,137,22,277,8566; 9337; 9316; 9331; 5090; 9327; 8452,,GSK3A_HUMAN(S21),DP0000623
melanoma skin cancer,increased,19996208,413,40,227,9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558,,GSK3B_HUMAN(S9),DP0000624
breast cancer,increased,20101225,1,0,0,,,ESR1_HUMAN(Y52),DP0000625
breast cancer,increased,20101225,1,0,0,,,ESR1_HUMAN(Y219),DP0000626
Alzheimer's disease,decreased,22278060,413,40,227,9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558,,GSK3B_HUMAN(S9),DP0000627
Alzheimer's disease,increased,22278060,86,38,14,,,MAPT_HUMAN(T231),DP0000628
MI,increased,23000962,4,26,658,,,PFN1_HUMAN(Y129),DP0000629
cardiomyopathy,increased,20716686,6,18,1,,inhibits cardiomyocyte hypertrophy,HDAC5_HUMAN(S279),DP0000630
type 2 diabetes,increased,20938636,211,14,33,5256; 2535; 4188; 50081; 2531,,PRKAA1_HUMAN(T183),DP0000631
breast ductal carcinoma,increased,20937773,5,2,0,,,CASP8_HUMAN(S387),DP0000632
non-small cell lung cancer,increased,21189248,2,17,8,,,ECT2_HUMAN(T359),DP0000633
Crohn disease,decreased,21123652,4,1,0,,,RIPK2_HUMAN(Y474),DP0000634
colorectal carcinoma,increased,21310943,8,3,0,,,ELAVL1_HUMAN(S318),DP0000635
Parkinson's disease,increased,21849493,42,5,0,23706,,SNCA_HUMAN(S129),DP0000636
PEL,increased,21819957,30,0,0,9551; 9554; 7960; 9549,,PTEN_HUMAN(S380),DP0000637
Kaposi's sarcoma,increased,21819957,30,0,0,9551; 9554; 7960; 9549,,PTEN_HUMAN(S380),DP0000638
Kaposi's sarcoma,increased,21819957,169,58,972,5006; 4856; 4857; 4858; 4854; 27036; 4851; 5316; 34411; 3985; 4803; 8520; 2211; 3945; 9865; 14733; 62016,,RPS6_HUMAN(S235),DP0000639
Kaposi's sarcoma,increased,21819957,585,11,18,43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038,,AKT1_HUMAN(T308),DP0000640
Kaposi's sarcoma,increased,21819957,164,70,1124,5006; 4856; 4857; 4858; 4854; 27036; 4851; 5316; 34411; 3985; 4803; 8520; 2211; 3945; 9865; 14733; 62016,,RPS6_HUMAN(S236),DP0000641
ovarian cancer,increased,21849418,121,22,172,9291; 11865; 5193; 5284; 9296,Higher BAD phosphorylation levels are seen in patients with incomplete response to platinum therapy. Lower levels of S75 phosphorylation were associated with increased overall survival.  ,BAD_HUMAN(S75),DP0000642
ovarian cancer,increased,21849418,118,53,216,9295; 5286; 4366,Higher BAD phosphorylation levels are seen in patients with incomplete response to platinum therapy. Lower levels of S75 phosphorylation were associated with increased overall survival.  ,BAD_HUMAN(S99),DP0000643
ovarian cancer,increased,21849418,45,62,166,9297,Higher BAD phosphorylation levels are seen in patients with incomplete response to platinum therapy. Lower levels of S75 phosphorylation were associated with increased overall survival.  ,BAD_HUMAN(S118),DP0000644
hepatocellular carcinoma,increased,21455220,46,35,740,3129; 3077; 3126; 4091; 4033; 12468,,MET_HUMAN(Y1234),DP0000645
hepatocellular carcinoma,increased,21455220,44,16,442,3129; 3077; 3126; 4091; 4033; 12468,,MET_HUMAN(Y1235),DP0000646
hepatocellular carcinoma,increased,21455220,95,14,0,9281,,TP53_HUMAN(S392),DP0000647
prostate cancer,increased,20679199,50,3,0,9741,hormone refractory human prostate cancer,EIF4E_HUMAN(S209),DP0000648
type 2 diabetes,decreased,15919790,585,11,18,43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038,,AKT1_HUMAN(T308),DP0000649
Bloom's syndrome,increased,17634426,197,29,29,2577; 9719; 5438; 9720; 20304; 4309; 5763; 85410; 9718; 80312,,H2AFX_HUMAN(S139),DP0000650
Bloom's syndrome,increased,17634426,165,5,0,2661; 2197; 12812,,CHEK2_HUMAN(T68),DP0000651
non-small cell lung cancer,increased,17653080,115,27,352,2236; 3777; 2234; 14565; 8543,,EGFR_HUMAN(Y1092),DP0000652
non-small cell lung cancer,mutation of site,17653080,6,0,0,,,EGFR_HUMAN(S768),DP0000653
colorectal cancer,increased,25003662,64,0,0,,"From 250 patient samples with metastatic CRC, 17.2% had high Y307-p levels and showed worse overall and progression-free survival. ",PPP2CA_HUMAN(Y307),DP0000654
breast cancer,increased,23636329,5,2,0,,enhances cell survival and invasiveness under hypoxia and correlates with poorer overall survival in breast cancer patients,AGO2_HUMAN(Y393),DP0000655
ASD autism spectrum,decreased,24180586,19,6,0,,"reduction of phosphorylated FMR1 in superior frontal cortex in children and adults with autism, a reduction also seen in Brodman area in adults, but not in children",FMR1_HUMAN(S500),DP0000656
breast cancer,increased,15193262,16,0,0,,tamoxifen resistance,ESR1_HUMAN(S305),DP0000657
breast cancer,increased,24960160,2,0,0,,Patients with p-Y36?negative tumors had shorter disease-free  and overall survival than those with p-Y36?positive tumors,ESR2_HUMAN(Y36),DP0000658
breast cancer,increased,22847294,70,40,558,25678; 2821; 14008; 14461; 88717, higher distant relapse and shorter disease-free survival,PLCG1_HUMAN(Y783),DP0000659
breast cancer,increased,22847294,12,19,85,, higher distant relapse and shorter disease-free survival,PLCG1_HUMAN(Y1253),DP0000660
ovarian epithelial carcinoma,increased,24655477,281,31,474,8556; 3283,High pY397 FAK is associated with improved overall survival,PTK2_HUMAN(Y397),DP0000661
glioma,increased,24358106,346,100,3046,70926; 6943; 2101,,SRC_HUMAN(Y419),DP0000662
kidney cancer,increased,19118035,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,renal cell carcinoma,AKT1_HUMAN(S473),DP0000663
kidney cancer,increased,19118035,24,0,1,,renal cell carcinoma,CDKN1B_HUMAN(T157),DP0000664
kidney cancer,decreased,19118035,25,0,6,,renal cell carcinoma,CDKN1B_HUMAN(T198),DP0000665
ovarian cancer,,24704825,0,22,4,,,SH2B3_HUMAN(S150),DP0000666
hypertrophic cardiomyopathy,,25802336,1,1,0,,,PTPN11_HUMAN(S189),DP0000667
hypertrophic cardiomyopathy,,25802336,1,0,0,,,PTPN11_HUMAN(T73),DP0000668
"breast cancer, triple negative",increased,25788226,2,14,29,,,PELP1_HUMAN(S1033),DP0000669
colorectal cancer,increased,25826088,19,1,0,,high pBcl-2-S87 had poor outcomes,BCL2_HUMAN(S87),DP0000670
prostate cancer,increased,25867060,11,1,0,,,RUNX2_HUMAN(S312),DP0000671
colorectal cancer,increased,25867068,3,34,611,,,FER_HUMAN(Y714),DP0000672
prostate cancer,increased,24793790,5,43,2,13589; 5426,promotes bone metastasis,TLN1_HUMAN(S425),DP0000673
breast adenocarcinoma,increased,24909179,121,22,172,9291; 11865; 5193; 5284; 9296,Her2 positive breast cancer PKACA and PIM1 overexpression promote resistance,BAD_HUMAN(S75),DP0000674
breast adenocarcinoma,increased,24909179,118,53,216,9295; 5286; 4366,Her2 positive breast cancer PKACA and PIM1 overexpression promote resistance,BAD_HUMAN(S99),DP0000675
Turner-like syndrome,decreased,20679480,50,31,142,9421,Noonan syndrome RAF1 mutations lead to dephosphorylation of S259 and impaired 14-3-3 binding.,RAF1_HUMAN(S259),DP0000676
fibrosarcoma of soft tissue,increased,21575192,321,70,3065,9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075,Y705 phosphorylation was significantly associated with tumor grade.,STAT3_HUMAN(Y705),DP0000677
breast cancer,increased,20696772,4,0,0,,associated with improved disease-free and overall survival,ESR2_HUMAN(S105),DP0000678
colorectal carcinoma,increased,21166956,16,0,0,,,LEPR_HUMAN(Y1141),DP0000679
colorectal carcinoma,increased,21166956,321,70,3065,9145; 4324; 4113; 9131; 4093; 9138; 4074; 4323; 8119; 52075,,STAT3_HUMAN(Y705),DP0000680
breast cancer,increased,21502402,3,12,0,,,TWIST1_HUMAN(S68),DP0000681
pancreatic cancer,increased,21474066,413,40,227,9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558,phosphorylation associated with poor overall survival,GSK3B_HUMAN(S9),DP0000682
pancreatic cancer,increased,21474066,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,phosphorylation associated with poor overall survival,AKT1_HUMAN(S473),DP0000683
pancreatic cancer,increased,21474066,130,14,106,2971; 5536; 2976,phosphorylation associated with poor overall survival,MTOR_HUMAN(S2448),DP0000684
Parkinson's disease,increased,21562258,42,5,0,23706,,SNCA_HUMAN(S129),DP0000685
Parkinson's disease,increased,20823226,1,1,0,,,PRKN_HUMAN(Y143),DP0000686
cardiomyopathy,decreased,20850451,26,5,28,,,MYBPC3_HUMAN(S284),DP0000687
cardiomyopathy,decreased,20850451,20,5,14,,,MYBPC3_HUMAN(S275),DP0000688
acute myelogenous leukemia,mutation of site,20622007,6,10,81,,,CBL_HUMAN(Y371),DP0000689
glioblastoma multiforme,increased,22891331,3,1,0,,shortened survival ,PTEN_HUMAN(Y240),DP0000690
acute lymphocytic leukemia,increased,24291004,5,9,6,85060,glucocorticoid resistance,NR3C1_HUMAN(S134),DP0000691
LGMD2A,decreased,25252031,1,1,0,,,CAPN3_HUMAN(S629),DP0000692
Alzheimer's disease,increased,26178297,32,5,16,2301,,PPP1R1B_HUMAN(T75),DP0000693
pancreatic carcinoma,increased,25658205,25,74,114,3455; 4494,human pancreatic ductal adenocarcinoma,DNM1L_HUMAN(S616),DP0000694
breast cancer,increased,25732845,7,17,1,,,CCDC88A_HUMAN(S1417),DP0000695
prostate cancer,increased,25868388,68,21,307,,correlates with decreased survival,PTK2_HUMAN(Y861),DP0000696
bladder cancer,decreased,26119935,78,30,180,13008; 29495; 4911; 57706,Yap phosphorylation decreased in cisplatin resistant tumors (xenograft model). ,YAP1_HUMAN(S127),DP0000697
endometrial cancer,increased,26218748,9,64,140,3241,"nuclear p-Pak4, pathogenesis of endometrial cancer especially in postmenopausal women",PAK4_HUMAN(S474),DP0000698
lung cancer,,26158630,4,32,171,6347,"co-localized with RSK, associated with overall survival of lung cancer patients",EPHA2_HUMAN(S897),DP0000699
breast cancer,increased,26272591,16,0,0,,AKAP13 mRNA levels correlate with ER-alpha S305 phosphorylation and poor outcome in patients who received tamoxifen treatment  ,ESR1_HUMAN(S305),DP0000700
hepatocellular carcinoma,,26505358,48,118,91,," there was a signifcant increase of stathmin expression in metastatic hepatic cancer, implying that the phosphorylation status of stathmin S25 may be involved in the invasion and metastasis of HCC",STMN1_HUMAN(S25),DP0000701
PAAND,mutation of site,27030597,4,6,0,,,MEFV_HUMAN(S242),DP0000702
CRPC,increased,26993766,21,27,30,3541,,NPM1_HUMAN(T199),DP0000703
CRPC,increased,26993766,7,25,21,,,NPM1_HUMAN(T237),DP0000704
CRPC,increased,26993766,7,20,17,,,NPM1_HUMAN(T234),DP0000705
ASD autism spectrum,decreased,25675530,1,1,0,,phosphorylation of this site is eliminated in individuals carrying the autism-associated mutation R704C,NLGN4X_HUMAN(T707),DP0000706
colorectal carcinoma; non-small cell squamous cell lung carcinoma,decreased,25679763,211,14,33,5256; 2535; 4188; 50081; 2531,,PRKAA1_HUMAN(T183),DP0000707
multiple sclerosis,increased,25801023,5,0,1,,MS brain samples,MLKL_HUMAN(T357),DP0000708
multiple sclerosis,increased,25801023,2,1,0,,MS brain samples,RIPK1_HUMAN(S14),DP0000709
multiple sclerosis,increased,25801023,9,2,0,31122; 65746; 44590,MS brain samples,RIPK1_HUMAN(S166),DP0000710
multiple sclerosis,increased,25801023,13,2,0,57220; 93654; 91702,MS brain samples,RIPK3_HUMAN(S227),DP0000711
multiple sclerosis,increased,25801023,2,1,1,,MS brain samples,RIPK1_HUMAN(S15),DP0000712
B cell lymphoma; non-Hodgkin's lymphoma; lymphoplasmacytic lymphoma; follicular lymphoma,increased,25788269,6,44,58,,,CSNK2B_HUMAN(S209),DP0000713
B cell lymphoma; non-Hodgkin's lymphoma; lymphoplasmacytic lymphoma; follicular lymphoma,increased,25788269,12,29,0,13248,,CDC37_HUMAN(S13),DP0000714
rheumatoid arthritis; SLE,increased,26005049,1,0,0,,,GRN_HUMAN(S81),DP0000715
kidney cancer,,21696810,40,61,745,4569,correlated with sarcomatoid renal cell carcinoma,CTTN_HUMAN(Y421),DP0000716
T-ALL,increased,26068967,2,1,0,,,IRAK1_HUMAN(T209),DP0000717
glioblastoma multiforme,increased,25257795,1,2,5,,,TNK2_HUMAN(Y635),DP0000718
non-small cell squamous cell lung carcinoma,increased,26555036,20,47,84,,CRMP2A is present within the nucleus in cancer cells,DPYSL2_HUMAN(S522),DP0000719
"obesity, hyperphagic",,26657864,3,37,80,,,IRS2_HUMAN(S391),DP0000720
HNSCC,increased,27498883,34,77,7,,worse clinical outcome,PDHA1_HUMAN(S232),DP0000721
tuberous sclerosis,increased,27516388,11,71,56,,,CTNND1_HUMAN(S268),DP0000722
Alzheimer's disease,increased,27557632,1,33,3,,,MARCKS_HUMAN(S147),DP0000723
Alzheimer's disease,increased,27557632,1,7,0,,,MARCKS_HUMAN(S132),DP0000724
Alzheimer's disease,increased,27557632,1,40,0,,,MARCKS_HUMAN(S46),DP0000725
Alzheimer's disease,increased,27557632,1,68,8,,,MARCKS_HUMAN(T150),DP0000726
breast cancer,increased,27494834,413,40,227,9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558,sites correlated and low expression associates with better survival in human breast cancers,GSK3B_HUMAN(S9),DP0000727
LBD,increased,27609071,22,34,35,9397,,DPYSL2_HUMAN(T514),DP0000728
Parkinson's disease,decreased,27609071,413,40,227,9325; 14332; 8566; 8466; 14310; 14630; 9323; 9336; 9322; 9331; 14026; 9327; 5558,Parkinson's disease dementia,GSK3B_HUMAN(S9),DP0000729
Parkinson's disease; LBD,decreased,27609071,75,125,4206,,Parkinson's disease dementia,GSK3B_HUMAN(Y216),DP0000730
leukemia,increased,27867011,2,1,0,,,ACAT1_HUMAN(Y407),DP0000731
Parkinson's disease,decreased,27903866,1,0,0,,,CRTC1_HUMAN(S215),DP0000732
mesothelioma,increased,18835652,26,39,1,9163; 13281,"in patient samples, merlin was truncated or phosphorylated on S518",NF2_HUMAN(S518),DP0000733
HSAN1,mutation of site,25567748,1,0,0,,,SPTLC2_HUMAN(S384),DP0000734
gastric carcinoma,increased,25888627,2,36,8,,associated with the poor prognosis of clinical gastric cancer,MORC2_HUMAN(S739),DP0000735
colorectal cancer,increased,25860929,402,8,0,9235; 8695; 9284; 9286; 8514; 12571; 4030,FBXW7-mutations,TP53_HUMAN(S15),DP0000736
Alzheimer's disease,increased,26317805,1,0,0,,,BACE1_HUMAN(T252),DP0000737
ASD autism spectrum,mutation of site,26255772,3,1,0,,,UBE3A_HUMAN(T485),DP0000738
psoriasis,increased,24863062,8,1,0,,,MAPK14_HUMAN(Y323),DP0000739
myelodysplastic syndrome,increased,26578796,21,55,158,,,ADD1_HUMAN(S726),DP0000740
hypertrophic cardiomyopathy,increased,26582913,1,3,1,,S348 phosphorylation is required for hypertrophy,DPF3_HUMAN(S348),DP0000741
T cell lymphoma,mutation of site,26551667,3,0,0,,"Sezary syndrome, cutaneous T cell lymphoma (CTCL)",CARD11_HUMAN(S615),DP0000742
multiple myeloma,increased,26517694,2,0,1,,,EZH2_HUMAN(S21),DP0000743
microlissencephaly,,21529751,2,13,31,,T246 in maybe involved in disease,NDE1_HUMAN(T246),DP0000744
non-small cell lung adenocarcinoma,increased,26947549,1,48,2,,high levels of phosphorylation had significantly reduced relapse-free survival (p < 0.01),SSFA2_HUMAN(S92),DP0000745
"breast cancer; breast cancer, triple negative",increased,26923594,346,100,3046,70926; 6943; 2101,higher in basal subtype BC;TNBC,SRC_HUMAN(Y419),DP0000746
"obesity, hyperphagic",increased,27151441,7,12,47,,,HIST1H2BB_HUMAN(S36),DP0000747
breast cancer,decreased,27335110,4,1,0,,,NOTCH1_HUMAN(T2511),DP0000748
breast cancer,decreased,21859709,1,44,1048,,enhances breast cancer cell survival,TFRC_HUMAN(Y20),DP0000749
breast cancer,increased,27605043,127,30,72,12716,primary breast cancer and lymph node metastases tissues,CAMK2A_HUMAN(T286),DP0000750
breast cancer,increased,27816489,2,0,0,,,FOSL1_HUMAN(T217),DP0000751
SBMA,increased,28003546,8,10,0,,,AR_HUMAN(S96),DP0000752
myotonic dystrophy type1,increased,24376746,3,8,1,,DM1-E2 (classic phenotype),CELF1_HUMAN(S28),DP0000753
myotonic dystrophy type1,,24376746,3,8,1,,"DM1-E1, DM1-CDM, no change",CELF1_HUMAN(S28),DP0000754
DM2,,24376746,3,8,1,,"DM2-PS, DM2-PDM, DM2-PROMM no change",CELF1_HUMAN(S28),DP0000755
neuroblastoma,increased,24349301,0,3,47,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),ADAM9_HUMAN(Y736),DP0000756
neuroblastoma,increased,24349301,1,11,108,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),ANTXR1_HUMAN(Y425),DP0000757
neuroblastoma,increased,24349301,0,11,67,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),ANKRD26_HUMAN(Y296),DP0000758
neuroblastoma,increased,24349301,11,19,864,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),APP_HUMAN(Y757),DP0000759
neuroblastoma,increased,24349301,0,18,604,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),CD46_HUMAN(Y357),DP0000760
neuroblastoma,increased,24349301,31,126,3845,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),CDK2_HUMAN(Y15),DP0000761
neuroblastoma,increased,24349301,15,47,894,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),CDK5_HUMAN(Y15),DP0000762
neuroblastoma,increased,24349301,0,18,604,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),CD46_HUMAN(Y387),DP0000763
neuroblastoma,increased,24349301,151,140,3902,4539; 14566; 9111,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),CDK1_HUMAN(Y15),DP0000764
neuroblastoma,increased,24349301,23,115,1764,2543,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),CDK1_HUMAN(T14),DP0000765
neuroblastoma,increased,24349301,4,35,735,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),CTNND1_HUMAN(Y96),DP0000766
neuroblastoma,increased,24349301,0,5,125,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),CNNM3_HUMAN(Y301),DP0000767
neuroblastoma,increased,24349301,0,4,118,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),JUP_HUMAN(Y480),DP0000768
neuroblastoma,increased,24349301,1,9,366,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),DDR2_HUMAN(Y740),DP0000769
neuroblastoma,increased,24349301,1,9,409,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),DDR2_HUMAN(Y736),DP0000770
neuroblastoma,increased,24349301,2,55,860,8244; 8862,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),EPHA2_HUMAN(Y772),DP0000771
neuroblastoma,increased,24349301,0,35,1220,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),ESYT1_HUMAN(Y822),DP0000772
neuroblastoma,increased,24349301,0,7,118,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),EIF3C_HUMAN(Y881),DP0000773
neuroblastoma,increased,24349301,4,12,137,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),CCDC88A_HUMAN(Y1799),DP0000774
neuroblastoma,increased,24349301,1,8,66,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),FGFR2_HUMAN(Y656),DP0000775
neuroblastoma,increased,24349301,75,125,4206,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),GSK3B_HUMAN(Y216),DP0000776
neuroblastoma,increased,24349301,0,6,33,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),HIST1H2BJ_HUMAN(Y43),DP0000777
neuroblastoma,increased,24349301,0,14,264,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),HNRNPM_HUMAN(Y64),DP0000778
neuroblastoma,increased,24349301,20,60,2054,70926; 6943; 2101,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),LYN_HUMAN(Y397),DP0000779
neuroblastoma,increased,24349301,16,31,455,80732; 3021,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),IGF1R_HUMAN(Y1161),DP0000780
neuroblastoma,increased,24349301,2,33,804,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),MAPK12_HUMAN(Y185),DP0000781
neuroblastoma,increased,24349301,13,38,707,3918; 3024; 2969,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),IGF1R_HUMAN(Y1165),DP0000782
neuroblastoma,increased,24349301,8,40,825,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),JAK2_HUMAN(Y570),DP0000783
neuroblastoma,increased,24349301,0,12,449,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),MYH10_HUMAN(Y1415),DP0000784
neuroblastoma,increased,24349301,0,3,126,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),TMIGD2_HUMAN(Y222),DP0000785
neuroblastoma,increased,24349301,0,7,161,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),MAP4K5_HUMAN(Y31),DP0000786
neuroblastoma,increased,24349301,34,31,455,80732; 3021,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),INSR_HUMAN(Y1185),DP0000787
neuroblastoma,increased,24349301,0,3,117,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),TMIGD2_HUMAN(Y188),DP0000788
neuroblastoma,increased,24349301,40,36,707,3918; 3024; 2969,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),INSR_HUMAN(Y1189),DP0000789
neuroblastoma,increased,24349301,0,1,3,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),UNK_HUMAN(Y232),DP0000790
neuroblastoma,increased,24349301,0,7,70,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),RBMX_HUMAN(Y255),DP0000791
neuroblastoma,increased,24349301,1,57,1101,5543; 8088,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),MPZL1_HUMAN(Y263),DP0000792
neuroblastoma,increased,24349301,0,5,19,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),TLN2_HUMAN(Y72),DP0000793
neuroblastoma,increased,24349301,0,50,2170,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),VIM_HUMAN(Y61),DP0000794
neuroblastoma,increased,24349301,0,2,22,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),SH2D3C_HUMAN(Y316),DP0000795
neuroblastoma,increased,24349301,0,7,63,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),PCDH1_HUMAN(Y897),DP0000796
neuroblastoma,increased,24349301,1,18,217,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),SRCIN1_HUMAN(Y268),DP0000797
neuroblastoma,increased,24349301,0,6,127,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),PLD3_HUMAN(Y7),DP0000798
breast cancer,increased,24166501,39,5,0,42101; 64508,"S167/S305 and Ser167 alone, but not Ser305 phosphorylation, are significantly associated disease-free survival in breast cancer patients",ESR1_HUMAN(S167),DP0000799
breast cancer,increased,24166501,16,0,0,,"S167/S305 and Ser167 alone, but not Ser305 phosphorylation, are significantly associated disease-free survival in breast cancer patients",ESR1_HUMAN(S305),DP0000800
Alzheimer's disease,increased,25192600,2,1,0,,blocking phosphorylation is neuroprotective in models,DNM1L_HUMAN(S40),DP0000801
Alzheimer's disease,increased,25192600,2,1,0,,blocking phosphorylation is neuroprotective in models,DNM1L_HUMAN(S44),DP0000802
Parkinson's disease,increased,25637461,42,5,0,23706,"Lower pS129 levels correlated with worse clinical condition at early stages, but better condition at later stages.",SNCA_HUMAN(S129),DP0000803
neuroblastoma,increased,24349301,1,5,6,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),SDC2_HUMAN(Y191),DP0000804
neuroblastoma,increased,24349301,0,8,318,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),PPP1CB_HUMAN(Y306),DP0000805
neuroblastoma,increased,24349301,0,7,76,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),RAB8A_HUMAN(Y5),DP0000806
neuroblastoma,increased,24349301,1,44,1536,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),TNS2_HUMAN(Y483),DP0000807
neuroblastoma,increased,24349301,0,21,566,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),TXNRD1_HUMAN(Y281),DP0000808
neuroblastoma,increased,24349301,0,6,121,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),F2R_HUMAN(Y420),DP0000809
neuroblastoma,increased,24349301,1,3,27,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),SHC3_HUMAN(Y406),DP0000810
neuroblastoma,increased,24349301,0,7,42,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),RPL35A_HUMAN(Y34),DP0000811
neuroblastoma,increased,24349301,0,11,74,,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),SCARF2_HUMAN(Y628),DP0000812
neuroblastoma,increased,24349301,35,58,1707,2055,increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line),PRKCD_HUMAN(Y313),DP0000813
vulvar cancer,increased,25849598,151,140,3902,4539; 14566; 9111,vulvar squamous cell carcinoma;  advanced tumor behaviors and aggressive features; decreased patient survival,CDK1_HUMAN(Y15),DP0000814
vulvar cancer,increased,25849598,24,40,83,9114,vulvar squamous cell carcinoma;  advanced tumor behaviors and aggressive features; decreased patient survival,CDK1_HUMAN(T161),DP0000815
vulvar cancer,increased,25849598,11,2,0,,vulvar squamous cell carcinoma;  advanced tumor behaviors and aggressive features; decreased patient survival,CCNB1_HUMAN(S126),DP0000816
prostate cancer,increased,26279575,3,77,278,13121,,SQSTM1_HUMAN(S272),DP0000817
prostate cancer,increased,26279575,3,71,136,13121,,SQSTM1_HUMAN(T269),DP0000818
Parkinson's disease,increased,26389970,19,12,0,62802; 37642; 70973,,UBA52-RPS27A-UBB-UBC_HUMAN(S65),DP0000819
chronic myelogenous leukemia,increased,21368869,1,30,1,,,YBX3_HUMAN(S134),DP0000820
breast cancer,increased,25074979,2,7,23,,poorer overall survival,SIRT6_HUMAN(S338),DP0000821
breast cancer,decreased,26701207,24,0,1,,correlates with low level of Myc protein,CDKN1B_HUMAN(T157),DP0000822
pheochromocytoma,mutation of site,20080836,2,0,0,,double C634Y/Y791F mutant,RET_HUMAN(Y791),DP0000823
Parkinson's disease,,22238344,1,1,0,,,PINK1_HUMAN(T313),DP0000824
AIS,mutation of site,22334658,1,0,0,,,AR_HUMAN(R407),DP0000825
hypertrophic cardiomyopathy,mutation of site,22389502,1,0,0,,Y141H,JPH2_HUMAN(Y141),DP0000826
breast cancer,increased,27130664,45,110,166,4191; 3426,higher incidence of recurrence,STMN1_HUMAN(S38),DP0000827
anal carcinoma,increased,27325299,4,0,0,,overall survival (OS) was superior for tumors showing a high pT273 caspase-8 signal ,CASP8_HUMAN(T273),DP0000828
breast cancer,mutation of site,27748765,9,0,0,,"mutated in breast cancer, CRISPR-Cas9 genome editing mutation Y537S. ",ESR1_HUMAN(Y537),DP0000829
Alzheimer's disease,increased,27834631,4,2,1,,,FCGR2B_HUMAN(Y273),DP0000830
"melanoma skin cancer; cancer, squamous cell carcinoma; BCC",increased,27893713,1,1,0,,,NFATC4_HUMAN(S259),DP0000831
cervical cancer,increased,27899378,1,1,0,,higher  PLK1  tyrosine  phosphorylation show  a  poor  5-year  survival  rate,PLK1_HUMAN(Y425),DP0000832
ALS,increased,26192745,40,1,0,,,TARDBP_HUMAN(S409),DP0000833
chronic myelogenous leukemia,decreased,26147002,234,32,392,4306; 5136; 4668; 4671; 9257; 9255; 5755; 9251,,MAPK8_HUMAN(T183),DP0000834
chronic myelogenous leukemia,decreased,26147002,5,0,0,,,SFN_HUMAN(S186),DP0000835
chronic lymphocytic leukemia; mantle cell lymphoma,increased,26210919,7,0,0,,,ALOX5_HUMAN(S524),DP0000836
colorectal cancer,increased,26212009,1,2,1,,,TCF3_HUMAN(S39),DP0000837
HNSCC,increased,26265441,12,17,36,,,RB1_HUMAN(T356),DP0000838
"colorectal carcinoma; ovarian cancer; non-small cell lung adenocarcinoma, surrounding tissue",increased,26248194,3,0,0,,,TOP1_HUMAN(S506),DP0000839
Fanconi's anaemia,decreased,26466335,34,94,61,3353,,STMN1_HUMAN(S16),DP0000840
Fanconi's anaemia,decreased,26466335,45,110,166,4191; 3426,,STMN1_HUMAN(S38),DP0000841
hepatocellular carcinoma,increased,26536659,7,25,21,,,NPM1_HUMAN(T237),DP0000842
hepatocellular carcinoma,increased,26536659,7,20,17,,,NPM1_HUMAN(T234),DP0000843
pancreatic cancer,increased,26676747,585,11,18,43506; 48646; 5106; 13842; 2965; 9275; 4056; 86758; 5056; 13038,high BAP28  or low AktT308 increased survival and response to gemcitabine,AKT1_HUMAN(T308),DP0000844
breast cancer,increased,26867768,3,22,285,,driving mammary carcinoma progression,BCAR1_HUMAN(Y267),DP0000845
breast cancer,increased,26867768,3,15,191,,driving mammary carcinoma progression,BCAR1_HUMAN(Y306),DP0000846
breast cancer,increased,26867768,2,17,284,,driving mammary carcinoma progression,BCAR1_HUMAN(Y287),DP0000847
breast cancer,increased,26867768,12,43,723,4014,driving mammary carcinoma progression,BCAR1_HUMAN(Y249),DP0000848
breast cancer,increased,26867768,3,30,698,,driving mammary carcinoma progression,BCAR1_HUMAN(Y234),DP0000849
RTT,mutation of site,27064487,1,0,0,,,MECP2_HUMAN(T158),DP0000850
Parkinson's disease,increased,27348587,4,2,11,,accumulates in Lewy bodies,SNCA_HUMAN(Y39),DP0000851
cystic fibrosis,mutation of site,27261451,1,0,0,,S1045Y-CFTR mutation,CFTR_HUMAN(S1045),DP0000852
non-small cell lung adenocarcinoma,increased,27212033,3,2,43,,,MYBL2_HUMAN(T487),DP0000853
hypertrophic cardiomyopathy,decreased,27525436,1,1,0,,,NOX4_HUMAN(Y566),DP0000854
cardiomyopathy,increased,27739424,25,74,114,3455; 4494,,DNM1L_HUMAN(S616),DP0000855
"breast cancer; obesity, hyperphagic",,28115363,3,0,0,,,SMAD4_HUMAN(T277),DP0000856
atherosclerosis,,25825525,5,0,0,,,NR1H3_HUMAN(S198),DP0000857
Alzheimer's disease,decreased,15126504,19,0,0,,,WWOX_HUMAN(Y33),DP0000858
Alzheimer's disease,increased,15126504,70,27,33,29957,,MAPT_HUMAN(S199),DP0000859
Alzheimer's disease,increased,15126504,86,38,14,,,MAPT_HUMAN(T231),DP0000860
Alzheimer's disease,increased,15126504,19,13,10,,,MAPT_HUMAN(S198),DP0000861
Alzheimer's disease,increased,15126504,37,13,5,,,MAPT_HUMAN(T212),DP0000862
Alzheimer's disease,increased,25556395,9,0,0,,accumulation in the parenchyma and vasculature and is largely restricted to late-stage AD,APP_HUMAN(S679),DP0000863
hepatocellular carcinoma,,25537504,197,29,29,2577; 9719; 5438; 9720; 20304; 4309; 5763; 85410; 9718; 80312,recurrence/metastasis of HCC,H2AFX_HUMAN(S139),DP0000864
non-small cell lung cancer,increased,25956913,33,3,11,2601,"Higher in later stages vs lower stage,  inverse correlation with E-cadherin/p120-catenin expression ",PAK1_HUMAN(T423),DP0000865
non-small cell lung cancer,increased,25956913,2,17,17,,"Higher in later stages vs lower stage,  inverse correlation with E-cadherin/p120-catenin expression ",CRK_HUMAN(S41),DP0000866
schizophrenia; bipolar disprder,increased,26049820,3,4,0,,"in BD cerebellum postmortem, in cerebellum schizophrenia postmortem",SP4_HUMAN(S770),DP0000867
ovarian epithelial carcinoma,increased,26068970,211,14,33,5256; 2535; 4188; 50081; 2531,spheroids,PRKAA1_HUMAN(T183),DP0000868
ovarian epithelial carcinoma,increased,26068970,25,2,3,3482,spheroids,STK11_HUMAN(S428),DP0000869
colorectal cancer,,26267535,1,0,0,,,COPS6_HUMAN(S148),DP0000870
PAH,increased,26248159,3,1,0,,,CAPN2_HUMAN(S50),DP0000871
PAH,decreased,26248159,2,1,2,,,CAPN2_HUMAN(S369),DP0000872
"breast cancer, triple negative",,26279746,2,5,7,,,EZH2_HUMAN(T416),DP0000873
melanoma skin cancer,increased,26275218,167,22,4,13050; 4526; 5883,"nuclear S1981 is associated with melanoma progression, strong S1981 was associated with worse overall survival ",ATM_HUMAN(S1981),DP0000874
breast cancer,decreased,26336132,3,15,45,,Patients with high expression of PRKD2 showed an increase in relapse-free survival.,VASP_HUMAN(S322),DP0000875
anal carcinoma,increased,27462786,4,0,0,,elevated levels of Plk3 and pT273 caspase-8  are correlated with favorable clinical outcome with  mitomycin C-based chemoradiotherapy (CRT),CASP8_HUMAN(T273),DP0000876
glioblastoma multiforme,increased,27485204,1,0,0,,High Cdc25A pY59 levels indicate poor prognosis.,CDC25A_HUMAN(Y59),DP0000877
prostate cancer,increased,28319065,5,83,28,,,DBN1_HUMAN(S142),DP0000878
ovarian cancer,increased,28415561,34,21,13,,shorter overall survival (OS) ,HSF1_HUMAN(S326),DP0000879
melanoma skin cancer,increased,28394346,4,1,0,,,KARS_HUMAN(S207),DP0000880
pancreatic carcinoma,increased,28388589,3,0,0,,,PIP5K1C_HUMAN(Y639),DP0000881
breast ductal carcinoma,increased,28415597,9,3,0,,improved cancer-specifc survival in ductal breast cancer ,AR_HUMAN(S516),DP0000882
"breast cancer, triple negative",increased,28415597,9,3,0,,poorer patient survival,AR_HUMAN(S516),DP0000883
breast ductal carcinoma,increased,28415597,1154,100,2017,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,improved cancer-specifc survival in ductal breast cancer ,MAPK3_HUMAN(T202),DP0000884
breast ductal carcinoma,increased,28415597,1126,149,4003,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,improved cancer-specifc survival in ductal breast cancer ,MAPK1_HUMAN(Y187),DP0000885
breast ductal carcinoma,increased,28415597,1177,129,3549,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,improved cancer-specifc survival in ductal breast cancer ,MAPK3_HUMAN(Y204),DP0000886
breast ductal carcinoma,increased,28415597,1104,117,2416,9106; 4370; 4374; 14196; 9101; 4375; 8544; 75165; 54240; 4376; 3510; 5726; 13148; 33370; 13214; 14227; 9488; 15892; 4377; 98168; 14095; 14474,improved cancer-specifc survival in ductal breast cancer ,MAPK1_HUMAN(T185),DP0000887
colorectal cancer,increased,28412249,3,0,7,,,TP53RK_HUMAN(S250),DP0000888
glioma,increased,28552616,2,1,0,,,ACSS2_HUMAN(S659),DP0000889
lung cancer,decreased,28581525,1,1,0,,,ZNF322_HUMAN(S391),DP0000890
breast cancer,increased,28566333,8,3,3,,CDK4 T172 phosphorylation best correlated with sensitivity to PD0332991,CDK4_HUMAN(T172),DP0000891
pancreatic cancer,increased,28363942,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000892
FMD,increased,28348077,16,79,999,4761,,FLNA_HUMAN(S2152),DP0000893
breast cancer,increased,28218905,3,24,374,8176,progression of metastatic cancer,LDHA_HUMAN(Y10),DP0000894
NAFLD,increased,28533219,1,4,0,,,SIRT1_HUMAN(S172),DP0000895
Alzheimer's disease,increased,28132667,2,0,0,,,PSEN1_HUMAN(S310),DP0000896
chronic lymphocytic leukemia,increased,28418900,2,63,5,,,USP7_HUMAN(S18),DP0000897
ovarian cancer,increased,28319064,63,43,112,8974; 8957; 8516; 4277; 9308; 11917,,RB1_HUMAN(S807),DP0000898
ovarian cancer,increased,28319064,12,17,36,,,RB1_HUMAN(T356),DP0000899
CCA,increased,28574228,5,16,0,,,SP1_HUMAN(S59),DP0000900
Parkinson's disease,increased,28636593,42,5,0,23706,,SNCA_HUMAN(S129),DP0000901
Parkinson's disease,increased,28636593,4,2,11,,,SNCA_HUMAN(Y39),DP0000902
non-small cell lung cancer,increased,28724430,1,2,6,,poor prognosis,SCD_HUMAN(Y55),DP0000903
non-small cell lung cancer,increased,28724430,115,27,352,2236; 3777; 2234; 14565; 8543,poor prognosis,EGFR_HUMAN(Y1092),DP0000904
clear cell kidney cancer,increased,28692056,16,24,637,,advanced pathologic stage,PTPN6_HUMAN(Y536),DP0000905
Alzheimer's disease,increased,28826672,1,0,0,,,LGMN_HUMAN(S226),DP0000906
Alzheimer's disease,increased,28826672,3,6,0,,,SRPK2_HUMAN(T492),DP0000907
Alzheimer's disease,increased,28760828,8,6,2,,,MAPT_HUMAN(S324),DP0000908
breast cancer; ovarian cancer,increased,29351847,1,1,0,27888,better survival,EZH2_HUMAN(T311),DP0000909
nephrosis,increased,28811476,16,24,637,,protects mice against lethal nephritis,PTPN6_HUMAN(Y536),DP0000910
SLE,,28811476,8,2,15,,,PTPN6_HUMAN(S591),DP0000911
Alzheimer's disease,increased,28814543,119,41,90,9632,,MAPT_HUMAN(S396),DP0000912
Alzheimer's disease,increased,28814543,106,50,116,39357,,MAPT_HUMAN(S202),DP0000913
Alzheimer's disease,increased,28814543,105,48,69,91600; 35834; 20194; 98523,,MAPT_HUMAN(S404),DP0000914
Alzheimer's disease,increased,28814543,110,41,4,9261; 5464; 91952; 2361,,JUN_HUMAN(S63),DP0000915
Alzheimer's disease,decreased,28946017,6,3,0,,decreased in AD brains,BACE1_HUMAN(S498),DP0000916
Huntington's disease,decreased,29162692,7,1,0,,,HTT_HUMAN(T3),DP0000917
hepatocellular carcinoma,increased; mutation of site,29225033,1,0,0,,,TP53_HUMAN(R249),DP0000918
chronic lymphocytic leukemia,increased,29763855,1,0,0,,,FCER2_HUMAN(S254),DP0000919
chronic lymphocytic leukemia,increased,29763855,1,0,0,,,FCER2_HUMAN(T314),DP0000920
chronic lymphocytic leukemia,increased,29763855,1,0,0,,,FCER2_HUMAN(S265),DP0000921
acute myelogenous leukemia,increased,18056483,367,6,1,9209; 9206; 97596; 9234; 9205,,RPS6KB1_HUMAN(T412),DP0000922
non-small cell lung cancer,mutation of site,20522446,6,0,0,,,EGFR_HUMAN(S768),DP0000923
non-small cell lung cancer,mutation of site,26870223,6,0,0,,,EGFR_HUMAN(S768),DP0000924
atrial fibrillation,mutation of site,30840693,2,4,0,,"rs3745297 (T>G, Ser96Ala) single nucleotide polymorphism (SNP) of HRC",HRC_HUMAN(S96),DP0000925
liver cancer,increased,31305264,1,1,0,,required for liver cancer tumorigenesis in immunocompetent mice,CD274_HUMAN(Y112),DP0000926
lung cancer; non-small cell lung adenocarcinoma; glioblastoma,increased,12612079,1,9,102,,,MAP4K4_HUMAN(T187),DP0000927
Parkinson's disease,increased,25104559,1,15,0,,,PEBP1_HUMAN(T42),DP0000928
breast cancer,increased,23007157,5,15,0,13908,,TRAF2_HUMAN(S11),DP0000929
Alzheimer's disease,increased,17683481,20,47,84,,,DPYSL2_HUMAN(S522),DP0000930
Alzheimer's disease,decreased,24985705,15,3,1,3764,,MAP3K5_HUMAN(S966),DP0000931
depression,increased,23918399,1,3,0,,,PACSIN2_HUMAN(S372),DP0000932
depression,increased,23918399,1,9,0,,,PACSIN2_HUMAN(S375),DP0000933
Kaposi's sarcoma,increased,25505069,23,0,0,,Inhhibition of NRF2 signaling may serve as a therapeutic approach to improve Kaposi's sarcoma pathology.,NFE2L2_HUMAN(S40),DP0000934
HNSCC,increased,17895985,3,3,0,,,AURKA_HUMAN(S51),DP0000935
Parkinson's disease,increased,21400129,42,5,0,23706,,SNCA_HUMAN(S129),DP0000936
breast cancer; lung cancer; colorectal cancer; esophageal cancer; gastric cancer,increased,23749209,8,0,0,,,XIAP_HUMAN(S87),DP0000937
breast cancer,increased,25479686,4,0,0,,,GATA3_HUMAN(S308),DP0000938
non-small cell squamous cell lung carcinoma,increased,20008839,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,predicts poor prognosis,AKT1_HUMAN(S473),DP0000939
non-small cell squamous cell lung carcinoma,increased,20008839,50,3,0,9741,predicts poor prognosis,EIF4E_HUMAN(S209),DP0000940
Alzheimer's disease,increased,21527912,9,0,0,,,APP_HUMAN(S679),DP0000941
type 2 diabetes,increased,21931634,233,47,1269,4306; 5136; 4668; 4671; 9257; 9255; 5755; 9251,after LPS treatment,MAPK8_HUMAN(Y185),DP0000942
HES,mutation of site,21224473,3,9,59,3170,mutated to Y849S,PDGFRA_HUMAN(Y849),DP0000943
HER2 positive breast cancer,increased,25342465,3,14,115,,,KRT19_HUMAN(S35),DP0000944
ovarian epithelial carcinoma,decreased,25083560,1,56,6,,,SMARCA4_HUMAN(S1452),DP0000945
multiple myeloma,decreased,25312647,1,3,14,,,SLAMF7_HUMAN(Y284),DP0000946
HNSCC,increased,25379016,3,0,0,,,TP73_HUMAN(T27),DP0000947
type 2 diabetes,increased,21931634,234,32,392,4306; 5136; 4668; 4671; 9257; 9255; 5755; 9251,after LPS treatment,MAPK8_HUMAN(T183),DP0000948
type 2 diabetes,decreased,21931634,211,14,33,5256; 2535; 4188; 50081; 2531,increased in Normal Glucose tolerance (NGT) volunteers after LPS treatment,PRKAA1_HUMAN(T183),DP0000949
ovarian cancer,increased,25237928,77,105,675,31866,,PDHA1_HUMAN(S293),DP0000950
ovarian cancer,decreased,25416196,2,1,0,,,PIK3C3_HUMAN(S164),DP0000951
ovarian cancer,decreased,25416196,10,92,1092,,,PEA15_HUMAN(S116),DP0000952
spinocerebellar ataxia type 1,increased,24903464,16,25,3,,,ATXN1_HUMAN(S775),DP0000953
glioblastoma,increased,28881571,2,1,2,,significantly shorter overall survival,AXL_HUMAN(Y779),DP0000954
Alzheimer's disease,decreased,28695147,4,16,0,,Triton X-100 insoluble fraction; associated with clinical and pathological severity,YWHAQ_HUMAN(S232),DP0000955
ADLB,decreased,28695147,4,16,0,,Triton X-100 insoluble fraction; associated with clinical and pathological severity,YWHAQ_HUMAN(S232),DP0000956
DLB,decreased,28695147,4,16,0,,Triton X-100 insoluble fraction; associated with clinical and pathological severity,YWHAQ_HUMAN(S232),DP0000957
Alzheimer's disease,increased,28758999,16,1,0,91689; 37333,,MLKL_HUMAN(S358),DP0000958
Alzheimer's disease,increased,28758999,5,0,1,,,MLKL_HUMAN(T357),DP0000959
colorectal cancer,increased,29344170,2,93,4,,poor prognosis,HNRNPA1_HUMAN(S6),DP0000960
CTE,increased,29298849,86,38,14,,colocalization of pT175 tau with the active pGSK3B,MAPT_HUMAN(T231),DP0000961
CTE,increased,29298849,8,8,0,,colocalization of pT175 tau with the active pGSK3B,MAPT_HUMAN(T175),DP0000962
ALS; CTE,increased,29298849,8,8,0,,CTE with ALS,MAPT_HUMAN(T175),DP0000963
ALS; CTE,increased,29298849,86,38,14,,CTE with ALS,MAPT_HUMAN(T231),DP0000964
ALS,mutation of site,29021214,1,1,0,,,CCNF_HUMAN(S621),DP0000965
hypertrophic cardiomyopathy,increased,29294329,7,51,347,,S573 is increased in the setting of pressure overload-induced cardiac hypertrophy.,PPP2R5D_HUMAN(S573),DP0000966
PAH,increased,29070699,77,105,675,31866,,PDHA1_HUMAN(S293),DP0000967
glioblastoma,increased,29232556,2,37,2,19386,,ATG4B_HUMAN(S383),DP0000968
acute myelogenous leukemia,increased,29431698,1,32,1,,AML chemotherapy resistance ,MEF2C_HUMAN(S222),DP0000969
diabetes mellitus,decreased,29467334,2,5,0,,,CRYAA_HUMAN(T148),DP0000970
glioblastoma,increased,29669288,1,0,0,,"stability of TRIM9s-MKK6-p38 complex, and it maintains the high activation state of p38 signaling to suppress glioblastoma progression",TRIM9_HUMAN(S76),DP0000971
glioblastoma,increased,29669288,1,0,0,,"stability of TRIM9s-MKK6-p38 complex, and it maintains the high activation state of p38 signaling to suppress glioblastoma progression",TRIM9_HUMAN(S80),DP0000972
Alzheimer's disease; Huntington's disease,decreased,22433863,3,0,0,,,CASP6_HUMAN(S257),DP0000973
liver disease,,15368451,14,26,13,,chronic noncirrhotic hepatitis C virus (HCV) or cirrhosis,KRT18_HUMAN(S34),DP0000974
liver disease,,15368451,26,8,23,,chronic noncirrhotic hepatitis C virus (HCV) or cirrhosis,KRT8_HUMAN(S432),DP0000975
liver disease,,15368451,16,12,14,,chronic noncirrhotic hepatitis C virus (HCV) or cirrhosis,KRT18_HUMAN(S53),DP0000976
liver disease,,15368451,26,8,9,,chronic noncirrhotic hepatitis C virus (HCV) or cirrhosis,KRT8_HUMAN(S74),DP0000977
mutation causing Brugada Syndrom,mutation of site,24795344,4,1,1,,expression of R526H and S528A channels were reduced compared with WT,SCN5A_HUMAN(S528),DP0000978
spinocerebellar ataxia type 1,increased,29758256,16,25,3,,Inhibition of phosphorylation at S776 results in degradation of ataxin which leads to delayed onset of ataxia,ATXN1_HUMAN(S775),DP0000979
atherosclerosis,deletion of site,23754392,4,19,1,2327,,SIRT1_HUMAN(S27),DP0000980
atherosclerosis,deletion of site,23754392,6,48,9,2314,,SIRT1_HUMAN(S47),DP0000981
Alzheimer's disease; AD,increased,25134727,40,1,0,,,TARDBP_HUMAN(S410),DP0000982
breast cancer,decreased,20179208,16,79,999,4761,,FLNA_HUMAN(S2152),DP0000983
breast cancer,decreased,20179208,2,69,16,,,FLNA_HUMAN(S1459),DP0000984
Huntington's disease; LBD; ADLB,increased,20126313,6,0,1,,,ELK1_HUMAN(T417),DP0000985
"cancer, squamous cell carcinoma",increased,21795477,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0000986
Alzheimer's disease; AD,increased,25134727,40,1,0,,,TARDBP_HUMAN(S409),DP0000987
breast cancer,decreased,21808024,56,37,30,46650,,MYC_HUMAN(T58),DP0000988
"breast cancer, triple negative",increased,24637719,1,0,0,,,BIK_HUMAN(S124),DP0000989
colorectal cancer,decreased,28199842,1,24,5,,,EGLN1_HUMAN(S125),DP0000990
multiple myeloma,increased,24676687,2,1,0,,,STOML2_HUMAN(S17),DP0000991
Alzheimer's disease,increased,24116116,42,29,23,12885,,MAPT_HUMAN(T181),DP0000992
Alzheimer's disease,increased,24116116,86,38,14,,,MAPT_HUMAN(T231),DP0000993
multiple myeloma,increased,23012246,12,41,151,3556,,RPS6KA3_HUMAN(S227),DP0000994
occular surface disease,increased,26120275,19,0,0,,,WWOX_HUMAN(Y33),DP0000995
hepatocellular carcinoma,decreased,25893300,52,33,33,13748,,MYC_HUMAN(S62),DP0000996
hepatocellular carcinoma,decreased,25893300,1,0,0,,,CTDSP1_HUMAN(S245),DP0000997
T-ALL,mutation of site,25344755,1,1,0,,,NOTCH1_HUMAN(S2513),DP0000998
T-ALL,mutation of site,25344755,4,1,0,,,NOTCH1_HUMAN(T2511),DP0000999
T-ALL,mutation of site,25344755,1,1,0,,,NOTCH1_HUMAN(S2516),DP0001000
breast adenocarcinoma,increased,22273145,2,4,0,,,ROCK2_HUMAN(S1366),DP0001001
glioblastoma,increased,28881571,1,3,52,44463,significantly shorter overall survival,AXL_HUMAN(Y698),DP0001002
neuroblastoma,increased,28739902,1,0,0,,,ROCK2_HUMAN(T396),DP0001003
pancreatic ductal adenocarcinoma,increased,29363544,6,3,0,12914; 87995; 80738; 11927,,IRAK4_HUMAN(T345),DP0001004
pancreatic ductal adenocarcinoma,increased,29363544,139,4,0,4887; 3036; 5733; 3031; 4886; 4025; 3033; 13346,,RELA_HUMAN(S536),DP0001005
psoriasis,increased,29290690,17,16,180,9346,increase in western blot and in nuclei in lesion skin,RPS6KA1_HUMAN(T573),DP0001006
psoriasis,decreased,29290690,55,47,64,13397; 13588; 9341; 9335; 12032; 11989; 13575,increase in western blot and cytosolic in lesion skin,RPS6KA1_HUMAN(S380),DP0001007
psoriasis,increased,29290690,9,14,180,,increase in western blot and in nuclei in lesion skin,RPS6KA3_HUMAN(T577),DP0001008
psoriasis,decreased,29290690,11,18,59,13397; 13588; 9341; 9335; 12032; 11989; 13575,increase in western blot and cytosolic in lesion skin,RPS6KA3_HUMAN(S386),DP0001009
HBL,decreased,29159818,13,0,0,,C/EBPa-dependent CSCs are observed in patients with aggressive hepatoblastoma and in patients with a predisposition for liver cancer. ,CEBPA_HUMAN(S190),DP0001010
lung cancer,increased,29038488,5,60,173,,involved in lung cancer cell proliferation,HMGA1_HUMAN(S99),DP0001011
breast cancer,,28993511,1,10,6,,predictor  of  breast  cancer-specific  survival  and  relapse-free  survival  in  patients  with  estrogen  receptor (ER)-negative breast cancer,HMMR_HUMAN(T703),DP0001012
pancreatic cancer,increased,29228685,3,1,0,,correlated with high ASK1 expression; ASK1-mediated phosphorylation of EB1 may contribute to pancreatic cancer cell proliferation ,MAPRE1_HUMAN(T206),DP0001013
hepatocellular carcinoma,increased,29514980,1,0,0,,T59  phosphorylation is correlated with poor prognosis in HCC patients.,SREBF1_HUMAN(T59),DP0001014
non-small cell lung cancer,increased,29515166,1,0,0,,poor survival of NSCLC patients,GLS_HUMAN(S314),DP0001015
T cell lymphoma,increased,29511289,1,1,0,,,MAP3K7_HUMAN(T344),DP0001016
T cell lymphoma,increased,29511289,1,6,0,,,MAP3K7_HUMAN(T444),DP0001017
breast ductal carcinoma,decreased,16278670,4,0,0,,,PRLR_HUMAN(S349),DP0001018
colorectal carcinoma,increased,29783958,3,1,0,,,STRAP_HUMAN(T175),DP0001019
colorectal carcinoma,increased,29783958,2,0,0,,,MELK_HUMAN(S171),DP0001020
colorectal carcinoma,increased,29783958,3,1,0,,,MELK_HUMAN(T167),DP0001021
colorectal carcinoma,increased,29783958,3,0,0,,,STRAP_HUMAN(S179),DP0001022
glioblastoma,mutation of site,23728337,2,0,0,,"citated in this paper : TCGA portal, https://tcga-data.nci.nih.gov).  "" Dock180 was found to be mutated to L1250 in a clinical glioblastoma sample from a patient after treatment with temozolomide"".",DOCK1_HUMAN(S1250),DP0001023
breast cancer,mutation of site,22751113,1,6,0,,T387N mutation,GAB1_HUMAN(T387),DP0001024
breast ductal carcinoma,mutation of site,22751113,2,0,0,,Y83C mutation,GAB1_HUMAN(Y83),DP0001025
breast cancer,molecular association,22580604,1,2,4,,,RUNX3_HUMAN(T212),DP0001026
breast cancer,molecular association,22580604,1,6,6,,,RUNX3_HUMAN(S214),DP0001027
breast cancer,molecular association,22580604,2,3,0,,,RUNX3_HUMAN(T209),DP0001028
breast cancer,molecular association,22580604,1,5,21,,,RUNX3_HUMAN(T231),DP0001029
kidney cancer,increased,22580611,2,19,39,,,RALGAPA2_HUMAN(S486),DP0001030
kidney cancer,increased,22580611,2,7,54,,,RALGAPA2_HUMAN(T715),DP0001031
kidney cancer,increased,22580611,1404,19,44,88106; 9271; 3787; 4060; 5315; 9563; 4070; 9018; 15116; 4051; 5102; 4075; 5012; 4071; 4054; 4058; 11962; 2336; 2337; 12694,,AKT1_HUMAN(S473),DP0001032
FXS,decreased,17376973,19,6,0,,Dephosphorylated FMRP leads to decrease in synapse number and function.,FMR1_HUMAN(S500),DP0001033
Alzheimer's disease; DLB,increased,17761554,42,29,23,12885,,MAPT_HUMAN(T181),DP0001034
AC,increased,18065522,20,19,1,,in UM-X7.1 hamsters,GJA1_HUMAN(S255),DP0001035
glioma,increased,25434386,36,11,31,,,GRIN2B_HUMAN(S1303),DP0001036
Alzheimer's disease,decreased,24917152,2,79,42,,,EFHD2_HUMAN(S74),DP0001037
Alzheimer's disease,increased,25023775,9,0,0,,,APP_HUMAN(S679),DP0001038
occular surface disease,increased,25468890,13,6,7,8888,,BIRC5_HUMAN(T34),DP0001039
breast cancer,increased,21706030,2,13,3,,,BRCA1_HUMAN(S1191),DP0001040
breast cancer,increased,25486426,3,0,0,,metastasis,PIP5K1C_HUMAN(Y639),DP0001041
colorectal cancer,increased,17803936,1,0,0,,,DAPK1_HUMAN(Y490),DP0001042
glioblastoma multiforme,increased,25468898,2,0,0,,,DOCK1_HUMAN(S1250),DP0001043
breast cancer,increased,21706030,4,15,6,,,BRCA1_HUMAN(S1189),DP0001044
breast cancer,increased,21706030,6,4,2,,,BRCA1_HUMAN(S1497),DP0001045
prostate cancer,increased,23774214,3,3,2,,,ETV1_HUMAN(S216),DP0001046
hypertrophic cardiomyopathy,increased,20190034,367,6,1,9209; 9206; 97596; 9234; 9205,,RPS6KB1_HUMAN(T412),DP0001047
colorectal cancer,increased,17803936,1,0,0,,,DAPK1_HUMAN(Y491),DP0001048
mantle cell lymphoma,mutation of site,25419709,1,0,0,,,HAX1_HUMAN(S210),DP0001049
"cancer, squamous cell carcinoma",decreased,22114688,26,8,9,,,KRT8_HUMAN(S74),DP0001050
nephrosis,decreased,25404734,10,0,0,,,NPHS1_HUMAN(Y1217),DP0001051
breast cancer,increased,21808024,52,33,33,13748,,MYC_HUMAN(S62),DP0001052
Alzheimer's disease,increased,24757378,70,27,33,29957,,MAPT_HUMAN(S199),DP0001053
atrial fibrillation,,25437921,3,0,0,,Phosphorylation of T383 is not responsible for the phosphorylation-dependent loss of current in chronic AF.,KCNK3_HUMAN(T383),DP0001054
mantle cell lymphoma,deletion of site,25419709,1,0,0,,,FBXO25_HUMAN(S178),DP0001055
Alzheimer's disease,increased,24757378,74,21,26,43964; 49561; 53001,,MAPT_HUMAN(T205),DP0001056
Alzheimer's disease,increased,24757378,84,20,2,,,MAPT_HUMAN(S262),DP0001057
Alzheimer's disease,increased,24757378,32,7,0,,,MAPT_HUMAN(S422),DP0001058
Alzheimer's disease,increased,24757378,106,50,116,39357,,MAPT_HUMAN(S202),DP0001059
Alzheimer's disease,increased,24757378,86,38,14,,,MAPT_HUMAN(T231),DP0001060
"cancer, squamous cell carcinoma",decreased,22114688,26,8,23,,,KRT8_HUMAN(S432),DP0001061
